
Contents
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Reflexes and muscle power Reflexes and muscle power
-
Key reflexes Key reflexes
-
Absent or ↓ reflex Absent or ↓ reflex
-
↑ reflex ↑ reflex
-
Clonus Clonus
-
Reinforcement Reinforcement
-
Testing for muscle power Testing for muscle power
-
-
Cranial nerve lesions Cranial nerve lesions
-
Neuropathy Neuropathy
-
Dermatomes and peripheral nerve distribution Dermatomes and peripheral nerve distribution
-
Mononeuropathy Mononeuropathy
-
Common mononeuropathies Common mononeuropathies
-
Bell’s palsy Bell’s palsy
-
Management Management
-
-
Ramsay Hunt syndrome (herpes zoster oticus) Ramsay Hunt syndrome (herpes zoster oticus)
-
Morton’s metatarsalgia Morton’s metatarsalgia
-
Autonomic neuropathy Autonomic neuropathy
-
Management Management
-
-
Polyneuropathy Polyneuropathy
-
-
Polyneuropathy Polyneuropathy
-
Sensory neuropathy Sensory neuropathy
-
Motor neuropathy Motor neuropathy
-
Causes Causes
-
Initial investigations Initial investigations
-
Management Management
-
Specific polyneuropathies Specific polyneuropathies
-
Charcot–Marie–Tooth syndrome (peroneal muscular atrophy) Charcot–Marie–Tooth syndrome (peroneal muscular atrophy)
-
Guillain–Barré polyneuritis Guillain–Barré polyneuritis
-
Polio Polio
-
Refsum’s syndrome Refsum’s syndrome
-
-
-
Walking problems Walking problems
-
Abnormal gait Abnormal gait
-
Abnormal movements Abnormal movements
-
Antalgic gait Antalgic gait
-
Drunken gait Drunken gait
-
Foot drop Foot drop
-
Hemiplegic gait Hemiplegic gait
-
Frontal lesions Frontal lesions
-
Parkinsonian gait Parkinsonian gait
-
Scissor gait Scissor gait
-
Sensory ataxic gait Sensory ataxic gait
-
Waddling gait Waddling gait
-
-
-
Other movement problems Other movement problems
-
Abnormal gait Abnormal gait
-
Cramp Cramp
-
Dystonia Dystonia
-
Tardive dyskinesia Tardive dyskinesia
-
Patient information and support Patient information and support
-
-
Myoclonus Myoclonus
-
Treatment Treatment
-
-
Dyspraxia Dyspraxia
-
Tremor Tremor
-
Asterixis Asterixis
-
Athetosis Athetosis
-
Chorea Chorea
-
Ballismus/hemiballismus Ballismus/hemiballismus
-
Tics Tics
-
Gilles de la Tourette syndrome Gilles de la Tourette syndrome
-
-
-
Speech problems Speech problems
-
Hoarseness Hoarseness
-
Stammer Stammer
-
Dysarthria Dysarthria
-
Dysphasia Dysphasia
-
Myasthenia gravis Myasthenia gravis
-
Presentation Presentation
-
Management Management
-
Lambert–Eaton syndrome (or myasthenic syndrome) Lambert–Eaton syndrome (or myasthenic syndrome)
-
-
-
Patient support Patient support
-
Fits, faints, and funny turns Fits, faints, and funny turns
-
History History
-
Also check Also check
-
-
Examination Examination
-
Funny turns in small children Funny turns in small children
-
Epilepsy Epilepsy
-
Syncope Syncope
-
Diagnosis Diagnosis
-
Presyncope Presyncope
-
Simple faint/vasovagal attack Simple faint/vasovagal attack
-
-
Dizziness and giddiness Dizziness and giddiness
-
Hyperventilation and panic attacks Hyperventilation and panic attacks
-
Hypoglycaemia Hypoglycaemia
-
Abnormal perceptions Abnormal perceptions
-
-
Assessment of headache Assessment of headache
-
History History
-
Examination Examination
-
Investigation Investigation
-
Differential diagnosis and management Differential diagnosis and management
-
Meningism Meningism
-
-
Further information Further information
-
Migraine Migraine
-
Aura Aura
-
Atypical aura Atypical aura
-
-
Migraine headache Migraine headache
-
History, examination, and differential diagnosis History, examination, and differential diagnosis
-
Management of chronic migraineG Management of chronic migraineG
-
Trigger factors Trigger factors
-
Assessing severity Assessing severity
-
General measures General measures
-
ProphylaxisN ProphylaxisN
-
Alternative therapies Alternative therapies
-
-
Menstrual migraineN Menstrual migraineN
-
-
Further information Further information
-
Patient information and support Patient information and support
-
Other headaches and facial pain Other headaches and facial pain
-
Assessment and differential diagnosis of headache Assessment and differential diagnosis of headache
-
Migraine Migraine
-
Chronic daily headache Chronic daily headache
-
Tension type headacheN Tension type headacheN
-
Non-drug management Non-drug management
-
Drug therapy Drug therapy
-
-
Cluster headaches Cluster headaches
-
Management Management
-
-
Medication overuse (analgesic) headacheN Medication overuse (analgesic) headacheN
-
Management Management
-
-
Facial pain Facial pain
-
Trigeminal neuralgia Trigeminal neuralgia
-
Management Management
-
Refer to neurology if Refer to neurology if
-
-
-
Further information Further information
-
Patient information and support Patient information and support
-
Raised intracranial pressure Raised intracranial pressure
-
Benign intracranial hypertension Benign intracranial hypertension
-
Brain abscess Brain abscess
-
Intracranial tumours Intracranial tumours
-
Presentation Presentation
-
Differential diagnosis Differential diagnosis
-
Prognosis Prognosis
-
-
Hydrocephalus Hydrocephalus
-
Presentation and management Presentation and management
-
-
-
Further information Further information
-
Information and support for patients Information and support for patients
-
Intracranial bleeds Intracranial bleeds
-
Haemorrhagic stroke Haemorrhagic stroke
-
Subarachnoid haemorrhage (SAH) Subarachnoid haemorrhage (SAH)
-
Risk factors Risk factors
-
Presentation Presentation
-
Examination Examination
-
Action Action
-
-
Subdural haemorrhage Subdural haemorrhage
-
Risk factors Risk factors
-
Presentation Presentation
-
Differential diagnosis Differential diagnosis
-
Action Action
-
-
Extradural haemorrhage Extradural haemorrhage
-
Presentation Presentation
-
Action Action
-
-
-
Acute stroke Acute stroke
-
Causes Causes
-
Risk factors Risk factors
-
Presentation Presentation
-
Differential diagnosis Differential diagnosis
-
Transient ischaemic attack (TIA) Transient ischaemic attack (TIA)
-
Management of TIA Management of TIA
-
Amaurosis fugax Amaurosis fugax
-
-
Subarachnoid haemorrhage Subarachnoid haemorrhage
-
Secondary prevention of stroke Secondary prevention of stroke
-
Rehabilitation Rehabilitation
-
-
Further information Further information
-
Patient information and support Patient information and support
-
Secondary prevention of stroke Secondary prevention of stroke
-
After stroke After stroke
-
Screening for depression Screening for depression
-
Secondary stroke prevention Secondary stroke prevention
-
Lifestyle advice Lifestyle advice
-
Antiplatelet drugs Antiplatelet drugs
-
Oral anticoagulation Oral anticoagulation
-
Hypertension management Hypertension management
-
Cholesterol Cholesterol
-
-
Carotid stenosis and carotid endarterectomy Carotid stenosis and carotid endarterectomy
-
-
Further information Further information
-
Patient information and support Patient information and support
-
Parkinsonism and Parkinson’s disease Parkinsonism and Parkinson’s disease
-
Parkinsonism Parkinsonism
-
Causes Causes
-
Treatment of drug-induced parkinsonism Treatment of drug-induced parkinsonism
-
-
Steele–Richardson–Olszewski syndrome Steele–Richardson–Olszewski syndrome
-
Parkinson’s disease (PD) Parkinson’s disease (PD)
-
Non-motor symptoms Non-motor symptoms
-
Management Management
-
Screening for depression Screening for depression
-
Referral Referral
-
Rehabilitation Rehabilitation
-
Drug treatment Drug treatment
-
Dopamine receptor agonists Dopamine receptor agonists
-
Levodopa (or L-dopa) Levodopa (or L-dopa)
-
Other drugs Other drugs
-
Surgery Surgery
-
-
Driving Driving
-
Carers Carers
-
-
Further information Further information
-
Patient advice and support Patient advice and support
-
Multiple sclerosis Multiple sclerosis
-
Presentation Presentation
-
Common features Common features
-
-
Prognosis Prognosis
-
Management Management
-
Disease-modifying drugs Disease-modifying drugs
-
Natalizumab and fingolimod Natalizumab and fingolimod
-
Acute relapses Acute relapses
-
Management of symptoms and disability Management of symptoms and disability
-
-
-
Further information Further information
-
Patient advice and support Patient advice and support
-
Motor neurone disease and CJD Motor neurone disease and CJD
-
Motor neurone disease (MND) Motor neurone disease (MND)
-
Patterns of disease Patterns of disease
-
Clinical picture Clinical picture
-
Management Management
-
Drug therapy Drug therapy
-
Support Support
-
Symptom relief Symptom relief
-
-
Creutzfeldt–Jakob disease (CJD) Creutzfeldt–Jakob disease (CJD)
-
Presentation Presentation
-
Differential diagnosis Differential diagnosis
-
Management Management
-
-
General principles of rehabilitation General principles of rehabilitation
-
Common neurological rehabilitation problems Common neurological rehabilitation problems
-
-
Further information Further information
-
Patient advice and support Patient advice and support
-
Spinal cord conditions Spinal cord conditions
-
Quadriplegia and tetraplegia Quadriplegia and tetraplegia
-
Paraplegia Paraplegia
-
Incomplete spinal cord injuries Incomplete spinal cord injuries
-
Cauda equina lesion Cauda equina lesion
-
Transverse myelitis Transverse myelitis
-
Management Management
-
-
Syringomyelia Syringomyelia
-
General principles of rehabilitation General principles of rehabilitation
-
Common neurological rehabilitation problems Common neurological rehabilitation problems
-
Specific problems associated with spinal cord injury Specific problems associated with spinal cord injury
-
Autonomic dysreflexia (hyperreflexia) Autonomic dysreflexia (hyperreflexia)
-
Loss of temperature control Loss of temperature control
-
Infertility Infertility
-
Bowel/bladder function Bowel/bladder function
-
Spasticity Spasticity
-
UTI UTI
-
Pressure sores Pressure sores
-
Depression Depression
-
-
-
Patient advice and support Patient advice and support
-
Epilepsy Epilepsy
-
Epilepsy in children Epilepsy in children
-
Management of a fitting patient/status epilepticus Management of a fitting patient/status epilepticus
-
Management after first fit Management after first fit
-
Classification of seizure types Classification of seizure types
-
Todd’s palsy Todd’s palsy
-
Causes of epilepsy in adults Causes of epilepsy in adults
-
Assessment Assessment
-
Screening for depression Screening for depression
-
Long-term management of epilepsy Long-term management of epilepsy
-
Epilepsy and pregnancy Epilepsy and pregnancy
-
Mortality Mortality
-
Sudden unexplained death in epilepsy (SUDEP) Sudden unexplained death in epilepsy (SUDEP)
-
-
-
Further information Further information
-
Patient advice and support Patient advice and support
-
Management of epilepsy Management of epilepsy
-
Education Education
-
Drug therapy Drug therapy
-
Withdrawal of drug therapy Withdrawal of drug therapy
-
Seizure recurrence is more likely if Seizure recurrence is more likely if
-
-
Surgery Surgery
-
Vagus nerve stimulation Vagus nerve stimulation
-
Ketogenic diet Ketogenic diet
-
At review At review
-
Re-refer Re-refer
-
-
Muscle disorders Muscle disorders
-
Symptoms Symptoms
-
Signs Signs
-
Muscular dystrophies Muscular dystrophies
-
Myotonic dystrophy (dystrophia myotonia) Myotonic dystrophy (dystrophia myotonia)
-
Patient information and support Patient information and support
-
-
Toxic myopathies Toxic myopathies
-
Management Management
-
-
Acquired myopathy of late onset Acquired myopathy of late onset
-
Polymyositis Polymyositis
-
PoliomyelitisND PoliomyelitisND
-
Acute polio Acute polio
-
Prevention Prevention
-
Late effects of polio Late effects of polio
-
-
Motor neurone disease Motor neurone disease
-
Myasthenia gravis/Lambert–Eaton syndrome Myasthenia gravis/Lambert–Eaton syndrome
-
-
Other neurological syndromes Other neurological syndromes
-
von Recklinghausen’s disease (type 1 neurofibromatosis; NF1) von Recklinghausen’s disease (type 1 neurofibromatosis; NF1)
-
Management Management
-
Complications Complications
-
-
Type 2 neurofibromatosis (NF2) Type 2 neurofibromatosis (NF2)
-
Diagnosis Diagnosis
-
Management Management
-
Complications Complications
-
-
Ekbom’s syndrome (restless legs syndrome) Ekbom’s syndrome (restless legs syndrome)
-
Management Management
-
Patient support Patient support
-
-
Wernicke’s encephalopathy Wernicke’s encephalopathy
-
Management Management
-
-
Korsakoff’s syndrome Korsakoff’s syndrome
-
Gilles de la Tourette syndrome Gilles de la Tourette syndrome
-
Huntington’s disease (chorea) Huntington’s disease (chorea)
-
Friedreich’s ataxia Friedreich’s ataxia
-
-
Patient support Patient support
-
Neurological rehabilitation problems Neurological rehabilitation problems
-
General principles of rehabilitation General principles of rehabilitation
-
Fatigue Fatigue
-
Action Action
-
-
Depression and anxiety Depression and anxiety
-
Action Action
-
-
Emotionalism Emotionalism
-
Sexual and personal relationships Sexual and personal relationships
-
Communication problems Communication problems
-
Poor vision Poor vision
-
Respiratory infections Respiratory infections
-
Venous thromboembolism Venous thromboembolism
-
Motor impairment Motor impairment
-
Spasticity ± muscle and joint contractures Spasticity ± muscle and joint contractures
-
Pain Pain
-
Action Action
-
-
Bladder problems Bladder problems
-
Bowel problems Bowel problems
-
Skin breakdown Skin breakdown
-
-
Neurological assessment scales Neurological assessment scales
-
Glasgow Coma Scale Glasgow Coma Scale
-
Motor scoring scale Motor scoring scale
-
Disability severity scales Disability severity scales
-
Daily living scales Daily living scales
-
Quality of life scales Quality of life scales
-
Cognitive function tests Cognitive function tests
-
Mental health scales, Mental health scales,
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Cite
Reflexes and muscle power
Automatic responses. The reflex arc goes from the stimulus via a sensory nerve to the spinal cord and then back along a motor nerve to cause muscle contraction, without brain involvement.
Key reflexes
See Table 16.2. Record whether absent, present with reinforcement, normal, or brisk ± clonus.
Reflex . | Test . | Expected result . | Nerve roots . |
---|---|---|---|
Jaw | Ask the patient to let his mouth open slightly. Place a finger on the chin and tap the finger with a tendon hammer | Contraction of masseters and closure of mouth | Vth cranial nerve |
Gag | Touch the back of the patient’s pharynx on each side with a spatula, If absent, ask the patient whether he can feel the spatula—if he can, then Xth nerve palsy | Contraction of the soft palate | IXth/Xth cranial nerve |
Biceps | Tap a finger placed on the biceps tendon by letting the tendon hammer fall on it | Contraction of the biceps + elbow flexion | C5, C6 |
Supinator | Tap the lower end of the radius just above the wrist with the tendon hammer | Contraction of brachioradialis + elbow flexion | C5, C6 |
Triceps | Support elbow in flexion with one hand. Tap the triceps tendon with a tendon hammer held in the other hand | Contraction of triceps + elbow extension | C7, C8 |
Knee | Support the knees so that relaxed and slightly bent. Let the tendon hammer fall onto the infrapatellar tendon | Contraction of quadriceps + extension of knee | L3, L4 |
Ankle | Externally rotate the thigh and flex the knee. Let the tendon hammer fall onto the Achilles tendon | Contraction of gastrocnemius + plantar flexion of the ankle | S1 |
Abdominal | Lightly stroke the abdominal wall diagonally towards the umbilicus in each of the four abdominal quadrants | Abdominal wall contractions. When absent can be normal or indicate UMN or LMN lesion | T7–T12 |
Cremaster | ♂ patients only. Pre-warn the patient. Stroke the superior and medial aspect of the thigh in a downwards direction | Contraction of cremasteric muscle → raising of scrotum and testis on the side stroked. Absent in UMN and LMN lesions | L1 |
Anal | Scratch the perianal skin | Reflex contraction of the external sphincter. Absent in UMN and LMN lesions | S4, S5 |
Plantar | Pre-warn the patient. Run a blunt object up the lateral side of the sole of the foot, curving medially before the MTP joints | Flexion of big toe (if >1y old). Extension implies UMN lesion | S1 |
Reflex . | Test . | Expected result . | Nerve roots . |
---|---|---|---|
Jaw | Ask the patient to let his mouth open slightly. Place a finger on the chin and tap the finger with a tendon hammer | Contraction of masseters and closure of mouth | Vth cranial nerve |
Gag | Touch the back of the patient’s pharynx on each side with a spatula, If absent, ask the patient whether he can feel the spatula—if he can, then Xth nerve palsy | Contraction of the soft palate | IXth/Xth cranial nerve |
Biceps | Tap a finger placed on the biceps tendon by letting the tendon hammer fall on it | Contraction of the biceps + elbow flexion | C5, C6 |
Supinator | Tap the lower end of the radius just above the wrist with the tendon hammer | Contraction of brachioradialis + elbow flexion | C5, C6 |
Triceps | Support elbow in flexion with one hand. Tap the triceps tendon with a tendon hammer held in the other hand | Contraction of triceps + elbow extension | C7, C8 |
Knee | Support the knees so that relaxed and slightly bent. Let the tendon hammer fall onto the infrapatellar tendon | Contraction of quadriceps + extension of knee | L3, L4 |
Ankle | Externally rotate the thigh and flex the knee. Let the tendon hammer fall onto the Achilles tendon | Contraction of gastrocnemius + plantar flexion of the ankle | S1 |
Abdominal | Lightly stroke the abdominal wall diagonally towards the umbilicus in each of the four abdominal quadrants | Abdominal wall contractions. When absent can be normal or indicate UMN or LMN lesion | T7–T12 |
Cremaster | ♂ patients only. Pre-warn the patient. Stroke the superior and medial aspect of the thigh in a downwards direction | Contraction of cremasteric muscle → raising of scrotum and testis on the side stroked. Absent in UMN and LMN lesions | L1 |
Anal | Scratch the perianal skin | Reflex contraction of the external sphincter. Absent in UMN and LMN lesions | S4, S5 |
Plantar | Pre-warn the patient. Run a blunt object up the lateral side of the sole of the foot, curving medially before the MTP joints | Flexion of big toe (if >1y old). Extension implies UMN lesion | S1 |
Absent or ↓ reflex
Implies a breach in the reflex arc at:
Sensory nerve or root, e.g. neuropathy, spondylosis
Anterior horn cell, e.g. MND, polio
Motor nerve or root, e.g. neuropathy, spondylosis
Nerve endings, e.g myasthenia gravis, or
Muscle, e.g. myopathy
↑ reflex
Implies lack of higher control—an upper motor neurone lesion, e.g. post-stroke.
Clonus
Rhythmic involuntary muscle contraction due to abrupt tendon stretching, e.g. by dorsiflexing the ankle—associated with an UMN lesion.
Reinforcement
Method of accentuating reflexes. Use if a reflex seems absent. Ask patients to clench their teeth (to reinforce upper limb reflexes) or clench their hands and pull in opposite directions (to accentuate lower limb reflexes). This effect only lasts ~1s, so ask patients to perform the manoeuvre simultaneously with the tap from the tendon hammer.
Testing for muscle power
See Table 16.1
Joint . | Movement . | Nerve roots . | Joint . | Movement . | Nerve roots . |
---|---|---|---|---|---|
Shoulder | Abduction | C5,6 | Hip | Flexion | L1–3 |
Adduction | C6–8 | Extension | L4,5 & S1 | ||
Elbow | Flexion | C5,6 | Knee | Flexion | L5 & S1 |
Extension | C7,8 | Extension | L3,4 | ||
Wrist | Flexion | C7,8 | Ankle | Dorsiflexion | L4,5 |
Extension | C6,7 | Plantarflexion | S1,2 | ||
Fingers | Flexion | C8 | Toes | Extensors | L5,S1 |
Extension | C7 | Flexors | S2 | ||
Abduction | T1 |
Joint . | Movement . | Nerve roots . | Joint . | Movement . | Nerve roots . |
---|---|---|---|---|---|
Shoulder | Abduction | C5,6 | Hip | Flexion | L1–3 |
Adduction | C6–8 | Extension | L4,5 & S1 | ||
Elbow | Flexion | C5,6 | Knee | Flexion | L5 & S1 |
Extension | C7,8 | Extension | L3,4 | ||
Wrist | Flexion | C7,8 | Ankle | Dorsiflexion | L4,5 |
Extension | C6,7 | Plantarflexion | S1,2 | ||
Fingers | Flexion | C8 | Toes | Extensors | L5,S1 |
Extension | C7 | Flexors | S2 | ||
Abduction | T1 |
Test proximal muscle power by asking the patient to sit from lying, pull you towards him/herself, or rise from squatting.
Cranial nerve lesions
Table 16.3 summarizes cranial nerve lesions and their causes. Figure 16.1 shows the cutaneous innervation of the head and neck. Cranial nerves may be affected at any point from the nerve nucleus within the brainstem to the point of innervation. Think systematically about the level of the lesion. Potential sites:
Muscle
Neuromuscular junction
Along the course of the nerve outside the brainstem
Within the brainstem
Nerve . | Clinical test . | Causes . |
---|---|---|
I Olfactory | Smell—test each nostril for the ability to differentiate different smells | Trauma, frontal lobe tumour, meningitis |
II Optic | Acuity—Snellen chart Visual fields—compare with your own visual fields by standing directly in front of the patient with your head at the same level as theirs Pupils—size, shape, reaction to light, and accommodation Ophthalmoscopy—darken room, dilate pupil with 1 drop tropicamide 0.5% if needed, view optic disc (? pale, swollen), follow each vessel outwards to view each quadrant, track outwards to check lens and cornea | Monocular blindness—lesion in one eye or optic nerve (e.g. MS, giant cell arteritis) Bitemporal hemianopia—optic chiasm compression, e.g. pituitary adenoma, craniopharyngioma, internal carotid artery aneurysm Homonymous hemianopia—affects half the visual field on the side opposite the lesion. Caused by lesion beyond the optic chiasm, e.g. stroke, abscess, tumour |
III | Ptosis, large pupil, eye looks down- and outwards
| DM, giant cell arteritis, syphilis, posterior communicating artery aneurysm, idiopathic If pupil normal size, results fom DM or other vascular cause |
IV | Diplopia on looking down and in; may compensate by tilting head | Rare in isolation. May occur as a result of trauma to the orbit |
V Trigeminal | Motor—open mouth. Jaw deviates to the side of the lesion Sensory—corneal reflex lost first. Check all three divisions | |
VI | Horizontal diplopia on looking outwards | MS, pontine CVA, ↑ ICP |
VII Facial | Causes facial weakness and droop Ask to raise eyebrows, show teeth, puff out cheeks. • LMN lesion: all one side of face affected • UMN lesion: lower two-thirds of the face affected only | LMN—Bell’s palsy, polio, otitis media, skull fracture, cerebello pontine angle tumour, parotid tumour, herpes zoster (Ramsay Hunt syndrome UMN—stroke, tumour |
VIII Vestibulo- auditory | Auditory—ask to repeat a number whispered in 1 ear whilst you block the other Vestibular—ask about balance, check for nystagmus ( | Noise, Paget’s disease, Ménière’s disease ( |
IX, X | Gag reflex, palate moves → normal side on saying ‘Aah’ | Trauma, brainstem lesions, neck tumours |
XI | Trapezii—shrug shoulders against resistance Sternomastoid—turn head to right/left against resistance | Rare. Polio, syringomyelia, tumours near jugular foramen, stroke, bulbar palsy ( |
XII | Tongue deviates to the side of the lesion | Trauma, brainstem lesions, neck tumours |
Nerve . | Clinical test . | Causes . |
---|---|---|
I Olfactory | Smell—test each nostril for the ability to differentiate different smells | Trauma, frontal lobe tumour, meningitis |
II Optic | Acuity—Snellen chart Visual fields—compare with your own visual fields by standing directly in front of the patient with your head at the same level as theirs Pupils—size, shape, reaction to light, and accommodation Ophthalmoscopy—darken room, dilate pupil with 1 drop tropicamide 0.5% if needed, view optic disc (? pale, swollen), follow each vessel outwards to view each quadrant, track outwards to check lens and cornea | Monocular blindness—lesion in one eye or optic nerve (e.g. MS, giant cell arteritis) Bitemporal hemianopia—optic chiasm compression, e.g. pituitary adenoma, craniopharyngioma, internal carotid artery aneurysm Homonymous hemianopia—affects half the visual field on the side opposite the lesion. Caused by lesion beyond the optic chiasm, e.g. stroke, abscess, tumour |
III | Ptosis, large pupil, eye looks down- and outwards
| DM, giant cell arteritis, syphilis, posterior communicating artery aneurysm, idiopathic If pupil normal size, results fom DM or other vascular cause |
IV | Diplopia on looking down and in; may compensate by tilting head | Rare in isolation. May occur as a result of trauma to the orbit |
V Trigeminal | Motor—open mouth. Jaw deviates to the side of the lesion Sensory—corneal reflex lost first. Check all three divisions | |
VI | Horizontal diplopia on looking outwards | MS, pontine CVA, ↑ ICP |
VII Facial | Causes facial weakness and droop Ask to raise eyebrows, show teeth, puff out cheeks. • LMN lesion: all one side of face affected • UMN lesion: lower two-thirds of the face affected only | LMN—Bell’s palsy, polio, otitis media, skull fracture, cerebello pontine angle tumour, parotid tumour, herpes zoster (Ramsay Hunt syndrome UMN—stroke, tumour |
VIII Vestibulo- auditory | Auditory—ask to repeat a number whispered in 1 ear whilst you block the other Vestibular—ask about balance, check for nystagmus ( | Noise, Paget’s disease, Ménière’s disease ( |
IX, X | Gag reflex, palate moves → normal side on saying ‘Aah’ | Trauma, brainstem lesions, neck tumours |
XI | Trapezii—shrug shoulders against resistance Sternomastoid—turn head to right/left against resistance | Rare. Polio, syringomyelia, tumours near jugular foramen, stroke, bulbar palsy ( |
XII | Tongue deviates to the side of the lesion | Trauma, brainstem lesions, neck tumours |

Any cranial nerve may be affected by DM, MS, tumours, sarcoid, vasculitis or syphilis and >1 nerve may be affected by a lesion. Refer according to cause to ENT, ophthalmology, or neurology.
Neuropathy
Dermatomes and peripheral nerve distribution


Mononeuropathy
Lesions of individual peripheral (including cranial) nerves. Causes: trauma, compression, DM, leprosy. If >1 peripheral nerve is involved, the term mononeuritis multiplex is used. Causes: DM, sarcoid, cancer, PAN, amyloid, leprosy.
Common mononeuropathies
See Table 16.4.
Nerve involved . | Nerve roots . | Presentation . | Common causes . |
---|---|---|---|
Median | C5–T1 | Loss of sensation over lateral 3½ fingers and palm. Wasting of the thenar eminence Inability to flex the terminal phalanx of the thumb implies involvement of the anterior interosseous branch | Trauma (especially wrist lacerations), carpal tunnel syndrome ( |
Ulnar | C7–T1 | Weakness and wasting of interossei muscles (weakness of abduction of fingers) and claw hand deformity. Wasting of hypothenar eminence, sensory loss over medial 1½ fingers and ulnar side of the hand. Flexion of 4th and 5th fingers is weak if proximal lesion | Trauma or compression at the elbow ( |
Radial | C5–T1 | Sensory loss is variable but always includes the dorsal aspect of the root of the thumb. Wrist drop and weak extension of thumb and fingers | Compression against the humerus, trauma |
Sciatic | L4–S2 | Weakness of hamstrings and all muscles below the knee (foot drop). Loss of sensation below the knee laterally | Back injury, pelvic tumour |
Common peroneal | L4–S2 | Inability to dorsiflex the foot (foot drop), evert the foot, or extend the toes. Sensory loss over dorsum of the foot | Trauma |
Tibial | S1–S3 | Inability to stand on tiptoe, invert the foot or flex toes Sensory loss over sole | Trauma or entrapment |
Nerve involved . | Nerve roots . | Presentation . | Common causes . |
---|---|---|---|
Median | C5–T1 | Loss of sensation over lateral 3½ fingers and palm. Wasting of the thenar eminence Inability to flex the terminal phalanx of the thumb implies involvement of the anterior interosseous branch | Trauma (especially wrist lacerations), carpal tunnel syndrome ( |
Ulnar | C7–T1 | Weakness and wasting of interossei muscles (weakness of abduction of fingers) and claw hand deformity. Wasting of hypothenar eminence, sensory loss over medial 1½ fingers and ulnar side of the hand. Flexion of 4th and 5th fingers is weak if proximal lesion | Trauma or compression at the elbow ( |
Radial | C5–T1 | Sensory loss is variable but always includes the dorsal aspect of the root of the thumb. Wrist drop and weak extension of thumb and fingers | Compression against the humerus, trauma |
Sciatic | L4–S2 | Weakness of hamstrings and all muscles below the knee (foot drop). Loss of sensation below the knee laterally | Back injury, pelvic tumour |
Common peroneal | L4–S2 | Inability to dorsiflex the foot (foot drop), evert the foot, or extend the toes. Sensory loss over dorsum of the foot | Trauma |
Tibial | S1–S3 | Inability to stand on tiptoe, invert the foot or flex toes Sensory loss over sole | Trauma or entrapment |
Bell’s palsy
Facial palsy without other signs. Unknown cause—possibly viral. Peak age: 10–40y. ♂ = ♀. Lifetime incidence: ~1:65. Affects left and right side of the face equally often. Usually sudden onset—may be preceded by pain around the ear. Other possible symptoms: facial numbness; ↓ noise tolerance; disturbed taste on the anterior part of the tongue.
Management
~70% recover completely; 13% have insignificant sequelae; the remainder have permanent deficit. 85% improve in <3wk—reassure. Give prednisolone (25mg bd for 10d) if <72h after onset of symptomsR. Protect eye—tape lid shut and pad at night; glasses in the day ± artificial tears if drying. Refer:
If recovery is not starting after 3wk
For tarsorraphy if complete or long-standing palsy
If unacceptable cosmetic result—may benefit from plastic surgery
C. Bell (1774–1842)—Scottish anatomist and surgeon
Ramsay Hunt syndrome (herpes zoster oticus)
Severe pain in the ear precedes facial nerve palsy. Zoster vesicles appear around the ear, in the external ear canal, on the soft palate, and in the tonsillar fossa. Often accompanied by deafness ± vertigo which are slow to resolve and may result in permanent deficit. Pain usually abates after 48h but post-herpetic neuralgia can be a problem. If detected <24h after the rash appears, treatment with antivirals (e.g. aciclovir 800mg 5x/d for 1 wk) may be effective.
J. Ramsay Hunt (1872–1937)—US neurologist.
Morton’s metatarsalgia
p. 498
Autonomic neuropathy
Postural hypotension (dizziness or syncope on standing, after exercise or a large meal), impotence, inability to sweat, vomiting and dysphagia, diarrhoea or constipation, urinary retention or incontinence, Horner’s syndrome ( p. 300). Check BP lying and standing—a postural drop of ≥30/15mmHg is abnormal. Causes:
Primary autonomic failure No known cause. Occurs alone or as part of multisystem atrophy. Typically middle-aged/elderly men. Onset is insidious. Survival—rarely >10y after diagnosis
Ageing 25% >74y have postural hypotension. Review medication, discourage prolonged bed rest. Often associated with disordered thermoregulation, making elderly people prone to hypothermia. Exclude other disorders (e.g. DM, multisystem atrophy, drugs) before putting down to ageing alone
Drugs Common culprits—antihypertensives (e.g. thiazides), diuretics (over-diuresis), L-dopa, TCAs, phenothiazines, benzodiazepines
Polyneuropathies May be part of more general polyneuropathy, e.g. DM, Guillain–Barré syndrome, or alcoholic/nutritional neuropathy
Other causes Craniopharyngioma, vascular lesions, spinal cord lesions, tabes dorsalis, Chagas’ disease, HIV, familial dysautonomia
Management
Treat any underlying cause. Advise patients to stand slowly, raise the head of the bed at night, eat little and often, and ↓ carbohydrate and alcohol intake. Fludrocortisone (0.1mg/d, increasing prn–unlicensed) may help those most severely affected. An alternative (also unlicensed) is midodrine. Refer if diagnosis is unclear or simple measures are ineffective.
Polyneuropathy
p. 542
Polyneuropathy
Generalized disorder of peripheral nerves, including cranial and autonomic nerves. Distribution is bilateral, symmetrical, and widespread.
Sensory neuropathy
Presents as numbness, tingling, or burning sensation often affecting the extremities first (glove and stocking distribution) or causing clumsiness handling fine objects (e.g. needle).
Motor neuropathy
Presents as progressive weakness or clumsiness of hands, stumbling/falls on walking, respiratory difficulty (can progress rapidly). Examination: wasting and weakness most marked distally; reflexes are ↓ or absent.
Causes
See Table 16.5.
Inflammatory | Guillain–Barré syndrome (mostly motor) Chronic inflammatory demyelinating polyneuropathy (CDP) Sarcoidosis |
Metabolic | DM (mainly sensory) Renal failure (mainly sensory) Hypothyroidism Hypoglycaemia Mitochondrial disorders |
Vasculitis | Polyarteritis nodosa Rheumatoid arthritis Wegener’s granulomatosis |
Malignancy | Paraneoplastic syndromes (especially small cell lung cancer) Polycythaemia rubra vera |
Infection | HIV Syphilis Lyme disease Leprosy (mainly sensory) |
Vitamin deficiency | Lack of B1, B6, B12 (e.g. alcoholic) |
Inherited | Refsum’s syndrome Charcot–Marie–Tooth syndrome (mostly motor) Porphyria |
Toxins | Lead (mostly motor) Arsenic |
Drugs | Alcohol Cisplatin Isoniazid Vincristine Nitrofurantoin Less frequently: metronidazole, phenytoin |
Others | Paraproteinaemias, e.g. multiple myeloma, amyloidosis |
Inflammatory | Guillain–Barré syndrome (mostly motor) Chronic inflammatory demyelinating polyneuropathy (CDP) Sarcoidosis |
Metabolic | DM (mainly sensory) Renal failure (mainly sensory) Hypothyroidism Hypoglycaemia Mitochondrial disorders |
Vasculitis | Polyarteritis nodosa Rheumatoid arthritis Wegener’s granulomatosis |
Malignancy | Paraneoplastic syndromes (especially small cell lung cancer) Polycythaemia rubra vera |
Infection | HIV Syphilis Lyme disease Leprosy (mainly sensory) |
Vitamin deficiency | Lack of B1, B6, B12 (e.g. alcoholic) |
Inherited | Refsum’s syndrome Charcot–Marie–Tooth syndrome (mostly motor) Porphyria |
Toxins | Lead (mostly motor) Arsenic |
Drugs | Alcohol Cisplatin Isoniazid Vincristine Nitrofurantoin Less frequently: metronidazole, phenytoin |
Others | Paraproteinaemias, e.g. multiple myeloma, amyloidosis |
Initial investigations
Exclude common causes—check blood glucose, FBC, ESR, U&E, Cr and eGFR, LFTs, TFTs, plasma B12, autoimmune profile, syphilis serology.
Management
Treat cause if possible. Involve physiotherapists and OT. If sensory neuropathy care of the feet is important to minimize trauma and consequent disability. Refer if a cause is not found.
If rapid deterioration admit as acute medical emergency as ventilation may be needed.
Specific polyneuropathies
Charcot–Marie–Tooth syndrome (peroneal muscular atrophy)
Presents at puberty or in early adult life and begins with foot drop and weak legs. The peroneal muscles are the first to atrophy. The disease spreads to the hands then arms. Sensation and reflexes are also ↓. Unknown cause. Once diagnosis is confirmed treatment is supportive.
J.M. Charcot (1825–93) and P. Marie (1853–1940)—French neurologists; H.H. Tooth (1856–1925)—English neurologist.
Guillain–Barré polyneuritis
Develops within a few weeks of surgery, flu vaccination or infection (URTI, flu, VZ, HSV, CMV, EBV, Campylobacter, Mycoplasma). In 40% no precipitating event is found.
Presents with ascending motor neuropathy which may advance fast. Proximal muscles are more affected than distal muscles. Trunk, respiratory muscles, and cranial nerves are commonly affected.
If suspected admit immediately to hospital as an emergency. Ventilation on ITU is frequently required; 85% make a complete or near-complete recovery; 10% are unable to walk alone at 1y; mortality is 10%.
C. Guillain (1876–1961) and J.A. Barré (1880–1967)—French neurologists.
Polio
p. 579
Refsum’s syndrome
Rare autosomal recessive disorder which presents in the second decade or later with sensorimotor polyneuropathy, ataxia, visual, and/or hearing problems. Treatment involves dietary restriction (avoidance of chlorophyll-containing foods) and plasmapheresis.
S. Refsum (1907–1991)—Norwegian physician.
Walking problems

Common symptom in the elderly. Causes:
Musculoskeletal Osteoarthritis or RA, osteoporotic fractures, fractured neck of femur, osteomalacia, Paget’s disease, polymyalgia rheumatica
Psychological Depression, bereavement, fear of falling
Neurological Stroke, Parkinson’s disease, peripheral neuropathy
Spinal cord compression
Systemic Pneumonia, UTI, anaemia, hypothyroidism, renal failure, infection, hypothermia
Treat according to cause. Refer (e.g. to rapid response team, social services, or elderly care) if inadequate support at home, cause warrants referral, or no cause is found.
Abnormal gait
Gait means manner of walking. Abnormal gait can give clues to the underlying problem.
Abnormal movements
Normal gait is interrupted by abnormal movements, e.g. choreiform movements, athetoid movements or hemiballismus. May indicate underlying neurological problem, e.g. cerebral palsy, Huntington’s chorea.
Antalgic gait
Gait adjusts to try to minimize pain in a joint—usually OA hip. The patient leans towards the affected side and takes a rapid step on that side followed by a slower step on the contralateral side—check Trendelenburg’s sign ( p. 488).
Drunken gait
Apart from alcohol, the other major cause of drunken gait is a cerebellar lesion. Features:
Wide-based gait or reeling gait on a narrow base
Feet are often raised too high and placed over carefully, with the patient looking ahead
If a cerebellar lesion, the patient falls to the side of the lesion
Foot drop
Patients trip frequently or walk with a high stepping gait. On examination, patients are unable to walk on their heels and cannot dorsiflex their foot. Check ankle jerk. Causes:
Common peroneal palsy, e.g. due to trauma—normal ankle jerk
Sciatica—ankle jerk absent
L4, L5 root lesion—ankle jerk may be absent
Peripheral motor neuropathy, e.g. alcoholic—ankle jerk weak or absent
Distal myopathy—ankle jerk weak or absent
Motor neurone disease—↑ ankle jerk
Hemiplegic gait
Style of walking seen in patients with UMN lesions. Features:
Arm adducted and internally rotated, elbow flexed and pronated ± finger flexion
Foot is plantar flexed and the leg swings in a lateral arc
Frontal lesions
Marked unsteadiness—the feet appear stuck to the floor causing a wide-based, shuffling gait.
Parkinsonian gait
Seen in patients with Parkinson’s disease and other causes of parkinsonism. Features:
Shuffling gait Short steps, with the feet barely leaving the ground, producing an audible shuffling noise. May trip over small obstacles
Turning ‘en bloc’ Keeping the neck and trunk rigid, and requiring multiple small steps to accomplish a turn
Gait freezing Inability to move feet. May worsen in tight, cluttered spaces or when attempting to initiate gait
Festinant gait Flexed posture as if hurrying to keep up with feet
Lack of normal arm swing
Scissor gait
As the name implies, the patient walks as if his/her legs were like a pair of scissors. Associated with spastic paraplegia
Both legs are held rigid with plantar flexion of the ankle, extension of the knee, and adduction/internal rotation of the hips
The patient walks on tiptoe and the knees rub together/cross during the walking cycle
Often accompanied by complex movements of the upper limbs to assist the walking movements
Sensory ataxic gait
Loss of proprioception due to peripheral neuropathy or spinal cord disease (e.g. cervical spondylosis, MS, syphilis, combined degeneration of the cord) results in an ataxic gait similar to that seen with cerebellar disease. Check Romberg’s test. Features:
Broad-based gait with a tendency to stamp feet down clumsily
Patient tends to look at feet throughout the walking cycle
Romberg’s sign +ve
Waddling gait
Typically seen in patients with proximal myopathy, e.g. due to muscular dystrophy. Other causes: pregnancy, congenital dislocation of the hip. Features:
Broad-based gait. The pelvis drops to the side of the leg being raised
The patient moves his/her body and hips to accommodate this, resulting in a duck-like waddle in the swing phase
Commonly accompanied by ↑ forward curvature of the lower spine
Note abnormalities and any aids/assistance required.
Make sure that you can see the legs well
Ask the patient to stand up from a chair without support. If able to do that, repeat with feet together and/or with eyes closed
Ask the patient to stand still with feet together. If able to do that ask the patient to close his eyes and see what happens (Romberg’s sign)
Ask the patient to walk normally for ~5m, turn round, and walk back
Ask the patient to walk heel-to-toe (testing for cerebellar disease)
Ask the patient to stand with the feet together
With eyes open—testing cerebellar and posterior column function
With eyes closed—testing posterior column function
On toes alone—impossible with S1 lesions
On heels alone—impossible if L4/L5 lesion
Other movement problems
Abnormal gait
p. 544
Cramp
Painful muscle spasm. Common—especially at night and after exercise. Rarely associated with disease—salt depletion, muscle ischaemia, myopathy. Forearm cramps suggest motor neurone disease. Night cramps in the elderly may respond to quinine bisulphate 300mg nocte twice weekly.
Dystonia
Prolonged muscle contraction producing abnormal postures or repetitive movements.
Spasmodic torticollis Head is pulled to one side and held there by a contracting sternomastoid muscle. Treat with physiotherapy
Blepharospasm Involuntary contraction of the orbicularis oculi. If troublesome, consider treatment with diazepam (but be careful to avoid dependence) or refer for treatment with botulinum toxin
Writer’s cramp Spasm of the hand and forearm muscles on writing
Generalized dystonia Primary generalized dystonia is usually genetic. Specialist treatment from a neurologist is essential. First-line drug treatment is with levodopa. If that is ineffective, an anticholinergic drug (e.g. trihexyphenidyl) can be helpful in controlling muscle spasms and tremor. Second-line treatments may include clonazepam, tetrabenazine, baclofen, botulinum toxin injections. Deep brain stimulation may also be helpful
Secondary dystonia Symptoms of dystonia that result from drugs or other medical conditions. Includes: drug-induced dystonia (acute dystonia or tardive dyskinesia); dystonia associated with cerebral palsy; dystonia assosicated with Parkinson’s disease; dystonia associated with other brain injury or disease; and dystonia associated with metabolic conditions (e.g. Wilson’s disease)
Tardive dyskinesia
Involuntary chewing and grimacing movements, resulting from long-term neuroleptic treatment (metoclopramide and prochlorperazine are also possible causes). Withdraw neuroleptic—if no improvement after 3–6mo consider tetrabenazine 25–50mg tds po.
Patient information and support
The Dystonia Society 020 7793 3650
www.dystonia.org.uk
Myoclonus
Sudden, involuntary focal or general jerks. May be normal, especially if occurs when falling asleep. Other causes:
Neurodegenerative disease (e.g. CJD)
Myoclonic epilepsy
Benign essential myoclonus (generalized myoclonus beginning in childhood as muscle twitches, may be inherited as autosomal dominant)
Asterixis (metabolic flap—e.g liver failure, uraemia)
Treatment
If needed treat with sodium valproate or clonazepam.
Dyspraxia
Impairment of performance of complex movements despite preservation of ability to perform their individual components. Test by asking the patient to perform everyday tasks (e.g. ask to dress/undress), copy complex hand movements and do familiar sequences of movements (e.g. ‘head, shoulders, knees, and toes’).
Childhood
p. 916
Adults
Most common causes are stroke or space-occupying lesion. Involve rehabilitation services and OT.
Dressing dyspraxia Patient is unsure of the orientation of clothes on his/her body.
Constructional dyspraxia Difficulty in assembling objects or drawing (ask to draw 5-pointed star)
Gait dyspraxia Gait disorder although the lower limbs function normally—more common amongst the elderly
Tremor
Resting tremor Present at rest but abolished on voluntary movement. Most common cause—PD when tremor is rhythmic
Intention tremor Irregular large amplitude tremor worse on movement, e.g. reaching for something. Typical of cerebellar disease
Tremors on movement Thyrotoxicosis, anxiety, benign essential tremor (inherited), and drugs (e.g. β-agonists) cause a fine tremor abolished at rest. Alcohol and β-blockers may help
Asterixis
Intermittent lapses of an assumed posture. May involve arms, neck, tongue, jaw, and eyelids. Usually bilateral, absent at rest, and asynchronous on each side. Causes: liver failure (flapping tremor), heart failure, respiratory failure, renal failure, hypoglycaemia, barbiturate intoxication.
Athetosis
Slow, confluent, often rhythmic, purposeless movements of hands, tongue, fingers, or face. Causes: cerebral palsy, kernicterus.
Chorea
Non-rhythmic, jerky, purposeless movements (especially hands), with voluntary movements possible in between. Most common causes: cerebral palsy, Huntington’s chorea, Sydenham’s chorea.
Ballismus/hemiballismus
Large-amplitude, involuntary flinging movements of limbs. May occur after stroke, in Huntington’s disease or with high doses of levodopa for PD.
Tics
Brief, repeated, and stereotyped movements which are able to be suppressed voluntarily for a while. Common in children and usually resolve spontaneously. Consider clonazepam or clonidine if tics are severe.
Gilles de la Tourette syndrome
p. 911
Speech problems
Hoarseness
p. 936
Stammer
Disorder of rhythm and fluency of speech in which syllables, words, or phrases are repeated. ♂: ♀ ≈4:1. Cause: unknown. Can result in stress and embarrassment.
Younger children Often short-lived; usually resolves spontaneously
Older children/adults Refer to speech therapy
Dysarthria
Difficulty with articulation due to incoordination or weakness of the musculature of speech. Language is normal. Ask to repeat ‘baby hippopotamus’ or ‘British constitution’. Treat the cause if possible otherwise support with speech therapy and aids to communication. Causes: see Table 16.6.
Cause . | Characteristics . |
---|---|
Cerebellar disease | Slurring of speech as if drunk Speech is irregular in volume and scanning in quality |
Extrapyramidal disease, e.g. Parkinson’s disease | Soft, indistinct, and monotonous speech |
Pseudo-bulbar palsy, e.g. stroke (bilateral), MS, MND | Alteration of speech—typically nasal speech sounding like Donald Duck Difficulty swallowing or chewing Tongue is spastic and jaw jerk ↑ |
Bulbar palsy, e.g. MND, Guillain–Barré, alcoholic brainstem myelinolysis, 1° or 2° brainstem tumours, syringobulbia, polio, hyponatraemia | Speech—quiet, hoarse or nasal Loss of function of the tongue, muscles of chewing/swallowing ± facial muscles Flaccid, fasciculating tongue Jaw jerk normal or absent |
Palate paralysis | Nasal speech Asymmetric or absent gag reflex |
Myasthenia gravis | Slurring of speech when fatigued |
Cause . | Characteristics . |
---|---|
Cerebellar disease | Slurring of speech as if drunk Speech is irregular in volume and scanning in quality |
Extrapyramidal disease, e.g. Parkinson’s disease | Soft, indistinct, and monotonous speech |
Pseudo-bulbar palsy, e.g. stroke (bilateral), MS, MND | Alteration of speech—typically nasal speech sounding like Donald Duck Difficulty swallowing or chewing Tongue is spastic and jaw jerk ↑ |
Bulbar palsy, e.g. MND, Guillain–Barré, alcoholic brainstem myelinolysis, 1° or 2° brainstem tumours, syringobulbia, polio, hyponatraemia | Speech—quiet, hoarse or nasal Loss of function of the tongue, muscles of chewing/swallowing ± facial muscles Flaccid, fasciculating tongue Jaw jerk normal or absent |
Palate paralysis | Nasal speech Asymmetric or absent gag reflex |
Myasthenia gravis | Slurring of speech when fatigued |
Dysphasia
Impairment of language due to brain damage to the dominant hemisphere. The left hemisphere is dominant for 99% of right-handed people and 60% of left-handers. In most cases, due to stroke or brain tumour. Rarely due to head injury or dementia. Assessment and classification: see Table 16.7. Mixed pictures are common. Treatment:
Speech therapy may, or may not, be helpful
Support, e.g. dysphasia groups
Aids to communication, e.g. computers, picture boards
Assessment: Is speech fluent, grammatical, meaningful, and apt? If yes, dysphasia is unlikely. Comprehension: can the patient follow one, two, or multiple step commands? Repetition: can the patient repeat a phrase after you? Naming: can the patient name common and uncommon items? Reading and writing? Usually affected too. If not, question the diagnosis of dysphasia. |
Assessment: Is speech fluent, grammatical, meaningful, and apt? If yes, dysphasia is unlikely. Comprehension: can the patient follow one, two, or multiple step commands? Repetition: can the patient repeat a phrase after you? Naming: can the patient name common and uncommon items? Reading and writing? Usually affected too. If not, question the diagnosis of dysphasia. |
Characteristics of dysphasia . | Broca’s (expressive) . | Wernicke’s (receptive) . | Conduction . | Transcortical . |
---|---|---|---|---|
Fluent? | ✗ | ✓ | ✓ | ✓ or ✗ |
Repetition normal? | ✗ | ✗ | ✗ | ✓ |
Understanding impaired? | ✗ | ✓ | ✗ | ✓ or ✗ |
Characteristics of dysphasia . | Broca’s (expressive) . | Wernicke’s (receptive) . | Conduction . | Transcortical . |
---|---|---|---|---|
Fluent? | ✗ | ✓ | ✓ | ✓ or ✗ |
Repetition normal? | ✗ | ✗ | ✗ | ✓ |
Understanding impaired? | ✗ | ✓ | ✗ | ✓ or ✗ |
Myasthenia gravis
Autoimmune disease. Antibodies to the acetylcholine receptor cause a deficit of receptors at the neuromuscular junction → muscle weakness. Antibodies are detectable in 90%. ♀:♂ ≈2:1. Associated with thymic tumours and other autoimmune disease, e.g. RA, SLE, hyperthyroidism. Generally follows a relapsing or slowly progressive course. If thymoma present, 5y survival ≈ 30%.
Presentation
Young adults with easy fatigability of muscles. Commonly affected muscles are the:
Orbital muscles causing ptosis and diplopia, and
Bulbar muscles causing slurring of speech—ask to count to 50
Weakness is exacerbated by pregnancy, infection, drugs (e.g. β-blockers, opiates, tetracycline, quinine), climate change, emotion, and exercise.
Management
If suspected refer for confirmation by a neurologist and specialist treatment. Treated with:
Anticholinesterase, e.g. pyridostigmine
Immunosuppression with prednisolone, methotrexate, or azathioprine
Thymectomy → remission in 30% and benefit in another 40%
Plasmapheresis
Lambert–Eaton syndrome (or myasthenic syndrome)
Occurs in association with small cell carcinoma of the lung or rarely autoimmune disease. Differs from myasthenia gravis by the tendency to hyporeflexia. Autonomic involvement is common. Proximal limb muscles/trunk are most commonly involved. Specialist treatment is essential.
Patient support
Myaesthenia Gravis Association UK www.mgauk.org
Fits, faints, and funny turns
Blackouts, faints, and funny turns are all common presentations to general practice. The major questions which should be asked seeing an individual who has had a funny turn are:
Is it epilepsy?
If it is epilepsy, then what kind?
If it is not epilepsy, then is there another serious underlying cause, e.g. heart disease?
History
A good history from the patient and ideally from a witness is essential in the correct diagnosis. Ask:
What happened?
When and where? Particularly, did it start during sleep?
Were there any precipitating events?
Were there any warning signs (e.g. aura, feeling going to faint, etc.)?
Does the patient remember the whole episode? If not, which bits are missing and how long are the gaps?
Did the patient lose consciousness? Quite frequently, patients describe episodes of dizziness or unsteadiness/falling as ‘funny turns’
Did the patient jerk his/her limbs? If so, was the jerking generalized or restricted to one area of the body?
What did the patient look like during the attack? An eye witness account is helpful
Did anything else happen during the attack (e.g. tongue biting, incontinence)?
What happened after the attack? Was the patient conscious straight away? Was there disorientation, drowsiness, or headache?
Also check
General medical history, including cardiac history and history of other neurological symptoms
Psychiatric history—anxiety, depression, panic attacks?
Past medical history—birth trauma, febrile convulsions in childhood, significant head injury, and/or meningitis/encephalitis
Family history—epilepsy
Substance abuse? Drugs or alcohol?
Examination
Complete general and neurological examination. Particularly check for:
Skin changes Café-au-lait spots (neurofibromatosis); adenoma sebaceum (tuberous sclerosis); trigeminal capillary haemangioma (Sturge–Weber syndrome)
Cardiovascular abnormalities Heart rate and rhythm, murmurs, carotid bruits, BP
Focal neurological deficits Suggest presence of a structural neurological lesion
Funny turns in small children
p. 896
Epilepsy
p. 574
Syncope
Abrupt and transient loss of consciousness due to a sudden ↓ in cerebral perfusion. Common—prevalence ~6% adults. It has many causes, ranging from benign (vasovagal syncope) to fatal (sustained ventricular tachycardia); the prognosis depends on the cause.
Diagnosis
A typical attack takes the following pattern:
Prodromal symptoms Nausea, clammy sweating, blurring, greying and possible loss of vision, light-headedness, dizziness and tinnitus, yawning. The collection is characteristic
Anoxic phase Loss of consciousness, pallor, sweating, pupil dilatation, tachypnoea, bradycardia. Muscle tone is ↓, causing eyes to roll up and the patient to fall. May be accompanied by a few myoclonic jerks as the patient falls
Recovery In the horizontal position, skin colour, pulse, and consciousness usually return within seconds. If the patient is unable to fall and is kept upright a 2° anoxic seizure may occur
After-effects Confusion, amnesia, and drowsiness are not prolonged. Injury and incontinence are rare but may occur. Tongue biting is very rare
Presyncope
Is the term applied to a less severe attack with partial loss of consciousness and a near fall.
Simple faint/vasovagal attack
Common. Peripheral vasodilatation, bradycardia, and venous pooling → postural hypotension. Often cause is unclear, though ♀ > ♂. Known precipitants: fright (e.g. during venesection) or emotion. Exclude other reasons for loss of consciousness. No treatment needed—reassure.
Dizziness and giddiness
Distinguish between true vertigo (the illusion of rotatory movement—the room spinning) and a feeling of unsteadiness or light-headedness:
Vertigo p. 950
Imbalance Implies difficulty in walking straight, e.g. from disease of peripheral nerves, posterior columns, or cerebellum
Faintness The feeling of being about to pass out. Associated with some seizure disorders and a variety of non-neurological conditions (e.g. postural hypotension, vasovagal fainting; hyperventilation; hypoglycaemia; arrhythmias; cough syncope). Sometimes >1 element coexists
Hyperventilation and panic attacks
p. 1120
Usually history is diagnostic but occasionally, seizures of temporal lobe origin may have similar symptomatology.
Hypoglycaemia
Affects patients with DM—particularly those taking insulin or oral hypoglycaemic agents. Produces autonomic changes, e.g. pallor, sweating and tachycardia, and behavioural changes (confusion, altered personality). If action is not taken to ↑ blood sugar, coma ± fitting ensues— p. 1100.
Abnormal perceptions
(e.g hallucinations— p. 988).
Assessment of headache
Common presenting complaint. The skill lies in deciding which headaches are benign, needing no intervention, and which require action.
History
Is there >1 type of headache? Take a separate history for each.
Time When did the headaches start? New or recently changed headache calls for especially careful assessment. How often do they happen? Do they have any pattern? (e.g. constant, episodic, daily) How long do they last? Why is the patient coming to the doctor now? A headache diary over >8wk may help if long-standing headaches
Character Nature/quality, site, and spread of the pain. Associated symptoms, e.g. nausea/vomiting, visual disturbance, photophobia, neurological symptoms
Cause Predisposing and/or trigger factors; aggravating and/or relieving factors; relationship to menstrual cycle; family history
Response Details of medication used (type, dose, frequency, timing). What does the patient do, e.g. can the patient continue work?
Health between attacks Do headaches go completely or is the patient unwell between attacks? Other past/current medical problems
Anxieties and concerns Of the patient/family
Examination
In acute, severe headache, examine for fever and purpuric skin rash. In all cases check BP, brief neurological examination including fundi, visual acuity, and gait, palpation of the temporal region/sinuses for tenderness, and examination of the neck. In young children, measure head circumference and plot on a centile chart.

Fever and worsening headache ± purpuric rash/meningism
Thunderclap headache (reaching peak intensity in <5min)
Progressive headache, worsening over weeks
Headache associated with postural change, sneezing, coughing, or exercise
Recent head injury (<3mo)
Papilloedema
Change in personality/new cognitive or neurological deficit
New onset in a patient with a history of HIV or cancer.
Headache with atypical aura (>1h ± motor weakness)
Aura for first time and using CHC
Investigation
Often not needed. ESR if temporal arteritis is suspected.
Differential diagnosis and management
See Table 16.8. ↑ BP may cause acute or chronic headache. Direct treatment at the cause.
. | Cause . | Features . | Management . |
---|---|---|---|
Acute new headache | Meningitis | Fever, photophobia, stiff neck, rash | IV/IM penicillin V and immediate admission ( |
Encephalitis | Fever, confusion, ↓ conscious level | Immediate admission ( | |
Subarachnoid haemorrhage | ‘Thunder-clap’ or very sudden onset headache ± stiff neck | Immediate admission ( | |
Head injury | Bruising/injury; ↓ conscious level, periods lucidity, amnesia | Consider admission ( | |
Self-limiting viral illness | Vary. Often associated with other symptoms, e.g. coryza, sore throat, low-grade fever | Paracetamol/NSAID—review if worsens or if not settling in 2–3d | |
Sinusitis | Tender over sinuses ± history of URTI |
| |
Dental caries | Facial pain ± tenderness |
| |
Tropical illness | History of travel, fever |
| |
Acute recurrent headache | Migraine | Aura, visual disturbance, nausea/vomiting, triggers |
|
Cluster headache | Nightly pain in 1 eye for 2–3mo, then pain-free for >1y |
| |
Exertional or coital headache | Suggested by history of association | NSAID or propranolol before attacks | |
Trigeminal neuralgia | Intense stabbing pain lasting seconds in trigeminal nerve distribution |
| |
Glaucoma | Red eye, haloes, ↓ visual acuity, pupil abnormality |
| |
Subacute headache | Giant cell arteritis | >50y, scalp tenderness, ↑ ESR, rarely ↓ visual acuity |
|
Chronic headache | Tension type headache | Band around the head, stress, low mood |
|
Cervicogenic headache | Unilateral or bilateral; band from neck to forehead; scalp tenderness |
| |
Medication overuse | Rebound headache on stopping analgesics |
| |
↑ intracranial pressure | Worse on waking/sneezing, ↓ pulse, ↑ BP, neurological signs |
| |
Paget’s disease | >40y, bowed tibia, ↑ alk phos |
|
. | Cause . | Features . | Management . |
---|---|---|---|
Acute new headache | Meningitis | Fever, photophobia, stiff neck, rash | IV/IM penicillin V and immediate admission ( |
Encephalitis | Fever, confusion, ↓ conscious level | Immediate admission ( | |
Subarachnoid haemorrhage | ‘Thunder-clap’ or very sudden onset headache ± stiff neck | Immediate admission ( | |
Head injury | Bruising/injury; ↓ conscious level, periods lucidity, amnesia | Consider admission ( | |
Self-limiting viral illness | Vary. Often associated with other symptoms, e.g. coryza, sore throat, low-grade fever | Paracetamol/NSAID—review if worsens or if not settling in 2–3d | |
Sinusitis | Tender over sinuses ± history of URTI |
| |
Dental caries | Facial pain ± tenderness |
| |
Tropical illness | History of travel, fever |
| |
Acute recurrent headache | Migraine | Aura, visual disturbance, nausea/vomiting, triggers |
|
Cluster headache | Nightly pain in 1 eye for 2–3mo, then pain-free for >1y |
| |
Exertional or coital headache | Suggested by history of association | NSAID or propranolol before attacks | |
Trigeminal neuralgia | Intense stabbing pain lasting seconds in trigeminal nerve distribution |
| |
Glaucoma | Red eye, haloes, ↓ visual acuity, pupil abnormality |
| |
Subacute headache | Giant cell arteritis | >50y, scalp tenderness, ↑ ESR, rarely ↓ visual acuity |
|
Chronic headache | Tension type headache | Band around the head, stress, low mood |
|
Cervicogenic headache | Unilateral or bilateral; band from neck to forehead; scalp tenderness |
| |
Medication overuse | Rebound headache on stopping analgesics |
| |
↑ intracranial pressure | Worse on waking/sneezing, ↓ pulse, ↑ BP, neurological signs |
| |
Paget’s disease | >40y, bowed tibia, ↑ alk phos |
|
Meningism
Headache, stiff neck, and photophobia. Associated with meningitis. May also be seen with encephalitis and SAH.
Further information
NICE Headaches in young people and adults (2012) www.nice.org.uk
Migraine
Migraine affects 15% of the UK population. ♂:♀ ≈1:3. One in three experiences significant disability. Caused by disturbance of cerebral blood flow under the influence of 5HT.
Aura
Occurs with or without headache. Symptoms arise over ≥5min and last 5–60min before resolving completely. Diagnose if:
Visual symptoms, e.g. flickering lights, spots, lines; partial loss of vision
Sensory symptoms, e.g. numbness; paraesthesia and/or
Speech disturbance
Atypical aura
Consider referral for further investigation if: motor weakness; double vision; visual symptoms affecting only one eye; poor balance or ↓ level of consciousness.
Migraine headache
Moderate to severe unilateral or bilateral throbbing/pulsating headache that lasts 4–72h (1–72h in children) and prevents usual activities. May occur with or without aura and be associated with nausea/vomiting ± ↑ sensitivity to light/noise.
Episodic Occurs on <15d/mo
Chronic Occurs on ≥15d/mo over >3mo
History, examination, and differential diagnosis
p. 552
Combination therapy with:
Triptan (e.g. sumatriptan 50–100mg po)—choice depends on cost. Not effective if taken before the headache develops. Stops 70–85% attacks. Start with lowest dose and ↑ as needed. If consistently ineffective try an alternative triptan. Consider nasal triptan as first-line if aged 12–17y
NSAID (e.g. naproxen 500mg bd) or paracetamol (1g qds) ± antiemetic (e.g. prochlorperazine 5mg, metoclopramide 10mg, or domperidone 10–20mg)—even if no nausea/vomiting
If oral preparations are ineffective/not tolerated, offer metoclopramide 10mg pr or buccal prochlorperazine 3–6mg and consider adding a non-oral NSAID (e.g. diclofenac 100mg pr) or triptan (e.g. sumatriptan 20mg nasal spray or 6mg sc).
Do not offer ergots or opioids for the acute treatment of migraine.
Treatment of recurrence within the same attack
Repeat symptomatic treatments within their dose limitations—pre-emptively if recurrence is usual/expected. If using triptans, a second dose may be effective, but repeated dosing can cause rebound headache. Naratriptan and eletriptan are associated with relatively low recurrence rates.
Management of chronic migraineG
Aims to control symptoms and minimize impact on the patient’s life. Cure is not a realistic aim.
Trigger factors
Half have a trigger for their migraine. Consider:
Psychological factors Stress/relief of stress; anxiety/depression; extreme emotions, e.g. anger or grief
Environmental factors Loud noise, bright/flickering lights, strong perfume, stuffy atmosphere, VDUs, strong winds, extreme heat/cold
Food factors Lack of food/infrequent meals; foods containing monosodium glutamate, caffeine, and tyramine; specific foods, e.g. chocolate, citrus fruits, cheese; alcohol, especially red wine.
Sleep Overtiredness (physical/mental); changes in sleep patterns (e.g. late nights, weekend lie-in, shift work, holidays); long-distance travel
Health factors Hormonal changes (e.g. monthly periods, CHC, HRT, the menopause); ↑ BP; toothache or pain in the eyes, sinuses, or neck; unaccustomed physical activity
Assessing severity
Used to assess the impact of migraine symptoms on lifestyle.
Instructions Please answer the following questions about ALL the headaches you have had over the last 3mo. If you did not do the activity in the last 3mo, write 0.
1. On how many days in the last 3mo did you miss work or school because of your headache? | □ days | |
2. How many days in the last 3mo was your productivity at work or school ↓ by ≥½ because of your headaches? (Do not include days you counted in question 1 where you missed work or school) | □ days | |
3. On how many days in the last 3mo did you not do household work* because of your headache? | □ days | |
4. How many days in the last 3mo was your productivity in household work↓ by ≥½ because of your headaches? (Do not include days you counted in question 3 where you did not do household work) | □ days | |
5. On how many days in the last 3mo did you miss family, social, or leisure activities because of your headaches? | □ days | |
MIDAS score | TOTAL | □ days |
A. On how many days in the last 3mo did you have a headache? (lf a headache lasted more than 1 day, count each day) | □ days | |
B. On a scale of 0–10, on average, how painful were these headaches? (Where 0 = no pain at all, and 10 = pain as bad as can it be) | □ |
1. On how many days in the last 3mo did you miss work or school because of your headache? | □ days | |
2. How many days in the last 3mo was your productivity at work or school ↓ by ≥½ because of your headaches? (Do not include days you counted in question 1 where you missed work or school) | □ days | |
3. On how many days in the last 3mo did you not do household work* because of your headache? | □ days | |
4. How many days in the last 3mo was your productivity in household work↓ by ≥½ because of your headaches? (Do not include days you counted in question 3 where you did not do household work) | □ days | |
5. On how many days in the last 3mo did you miss family, social, or leisure activities because of your headaches? | □ days | |
MIDAS score | TOTAL | □ days |
A. On how many days in the last 3mo did you have a headache? (lf a headache lasted more than 1 day, count each day) | □ days | |
B. On a scale of 0–10, on average, how painful were these headaches? (Where 0 = no pain at all, and 10 = pain as bad as can it be) | □ |
Questions A and B measure the frequency of the migraine and the severity of pain. They are not used to reach the MIDAS score but provide extra information helpful for making treatment decisions.
Interpreting the MIDAS score . | |||
---|---|---|---|
I | Score: 0–5 | Minimal/infrequent disability | Tend to have little or no treatment needs. Can often manage with OTC medication. If infrequent severe attacks may require triptan |
II | Score: 6–10 | Mild/infrequent disability | May require medication for acute attacks, e.g. NSAID ± antiemetic or triptan |
III | Score: 11–20 | Moderate disability | Will need medication for acute attacks. Consider prophylaxis. Consider other causes for headaches, e.g. tension type headache |
IV | Score: ≥21 | Severe disability |
Interpreting the MIDAS score . | |||
---|---|---|---|
I | Score: 0–5 | Minimal/infrequent disability | Tend to have little or no treatment needs. Can often manage with OTC medication. If infrequent severe attacks may require triptan |
II | Score: 6–10 | Mild/infrequent disability | May require medication for acute attacks, e.g. NSAID ± antiemetic or triptan |
III | Score: 11–20 | Moderate disability | Will need medication for acute attacks. Consider prophylaxis. Consider other causes for headaches, e.g. tension type headache |
IV | Score: ≥21 | Severe disability |
General measures
Reassure. Instruct about management of acute attacks. A diary can be used to identify trigger factors, assess headache frequency, severity, medication usage/overusage, and response to treatment. Avoid trigger factors where possible. Give advice on relaxation techniques and stress management. Do not offer CHC to women with migraine, especially if aura ( p. 753).
ProphylaxisN
Consider if ≥4 attacks/mo or severe attacks. ↓ attacks by ~50%. Try a drug for 2mo before deeming it ineffective. If effective, continue for 6mo then review to consider ↓ dose slowly before stopping.
1st-line Propranolol S/R 80–160mg od/bd or topiramate 25–50mg od/bd—start at low dose and ↑ dose every 2–4wk; Topiramate is teratogenic and may interact with hormonal contraception
2nd-line Gabapentin (up to 1200mg/d in divided doses) or acupuncture (up to 10 sessions over 5–8wk)
3rd-line Botulinum type A toxin may be helpful for patients who have chronic migraine, do not have medication-overuse headache and have not responded to ≥3 different prophylactic medicationsN
Alternative therapies
Riboflavin 400mg od may ↓ frequency/intensity of headachesN; feverfew 200mg daily may↓ symptoms after 6wk useC.
Menstrual migraineN
Suspect if migraine occurs from 2d before to 3d after start of period on at least 2 out of 3 consecutive months (use headache diary). If predictable menstrual-related migraine that does not respond to standard acute treatment, consider frovatriptan (2.5mg bd) or zolmitriptan (2.5 mg bd/tds) on the days that migraine is expected.
>1 type of headache may coexist—50% migraine sufferers develop tension type headache resulting in background pain between attacks. Consider each separately.
Further information
Headaches in young people and adults (2012)
Migraine (chronic)—botulinum toxin type A (2012)
Patient information and support
Migraine Action Association 0116 275 8317
www.migraine.org.uk
Migraine Trust 020 7631 6970
www.migrainetrust.org
Other headaches and facial pain
Assessment and differential diagnosis of headache
p. 552
Migraine
p. 554
Chronic daily headache
Prevalence 4%. Defined as any headache that occurs >15d/mo. Common causes: tension-type headache, cervicogenic headache ( p. 474), medication-overuse headache, migraine, errors of refraction (usually headache is mild, frontal, in the eyes themselves, and absent on waking). Treat the cause (may be >1).
Tension type headacheN
Associated with stress and anxiety and/or functional or structural abnormalities of the head or neck. Prevalence ≈2%. ♀:♂ ≈2:1. Symptoms begin aged <10y in 15% patients. Prevalence ↓ with age. Family history of similar headaches is common (40%), but twin studies do not suggest a genetic basis. Distinguish between episodic and chronic tension-type headache:
Episodic Defined as headache lasting 30min–7d and occurring <180d/y (<15d/mo)
Chronic Headaches on ≥15d/mo (≥180d/y) for ≥3mo
In both cases pain:
Is bilateral, pressing, and/or tightening in quality
Of mild/moderate intensity
Is not associated with vomiting
Does not prohibit activities
Is not aggravated by physical activity
Non-drug management
Reassure no serious underlying pathology. Try measures to alleviate stress—relaxation; massage; yoga; exercise. Treat musculoskeletal symptoms with physiotherapy.
Drug therapy
Analgesics are of limited value and might make matters worse (see Medication-overuse headache).
Acute management Simple analgesia, e.g. paracetamol, ibuprofen. Avoid codeine-containing preparations and other opioids
Prophylaxis Acupuncture—up to 10 sessions over 5–8wk
Cluster headaches
Extremely painful headaches focussed around 1 eye with associated autonomic symptoms on that side (drooping eyelid, constricted pupil, red watery eye, runny or blocked nose, forehead sweating). Rare <20y of age. ♂:♀ ≈6:1. More common in smokers. Pain lasts 15–180min and occurs from 1x every 2d to 8x/day. Recurrences affect the same side. Onset is often predictable (1–2h after falling asleep; after alcohol). 2 patterns:
Episodic Remissions of >1mo
Chronic Remissions of <1mo in a 12mo period
Management
Refer for specialist advice/neuroimaging for first bout of cluster headache. Drug treatments:
Acute attack 100% oxygen (>12L/min) for 10–20min; 5HT1 agonists, e.g. sumatriptan (6mg sc or 20mg nasal)—stops 75% in <15min
Prophylaxis Consider verapamil 80mg tds/qds if attacks are frequent (needs ECG monitoring—seek specialist advice if unfamiliar with use). More effective if initiated early at the start of a new cluster. Refer for specialist advice if no response to verapamil.
Medication overuse (analgesic) headacheN
Persistent headache in patients with other causes of pain who are overusing analgesics. Affects 1 in 50 adults; ♀:♂ ≈5:1. Consider if headache develops/worsens when taking analgesic medication for ≥3mo. Implicated drugs include:
Triptans, opioids, ergots, or combination analgesics on ≥10d/mo
Paracetamol, aspirin, or NSAID on ≥15d/mo
Management
Explain the condition to the patient. Advise stopping overused medication abruptly for at least 1mo. Provide follow-up and support over 4–8wk; warn that symptoms may worsen initially (day 3–7) before improving. Review treatment of any underlying problem (e.g. migraine or chronic musculoskeletal pain). Consider specialist referral if taking strong opioids or recurrent, failed attempts to stop medication overuse.
Facial pain
Treat the cause. Common causes include: trigeminal neuralgia; temporomandibular joint disorders; dental disorders; sinusitis; migrainous neuralgia; shingles and post-herpetic neuralgia. No cause is found in many patients—it is then termed atypical facial pain. Atypical facial pain may respond to simple analgesia with paracetamol or NSAID. If this fails, try nerve painkillers, e.g. amitriptyline 10–75mg nocte. If troublesome symptoms, refer to ENT, maxillofacial surgery, or neurology.
Trigeminal neuralgia
Paroxysms of intense stabbing, burning, or ‘electric shock’ type pain, lasting seconds to minutes in the trigeminal (V) nerve distribution; 96% unilateral. Mandibular/maxillary > ophthalmic division. Between attacks there are no symptoms. Frequency of attacks ranges from hundreds/d to remissions lasting years. Pain may be provoked by movement of the face (talking, eating, laughing) or touching the skin (shaving, washing). Can occur at any age but more common >50y. ♀ > ♂. Unknown cause but associated with MS.
Management
Spontaneous remission may occur.
Carbamazepine Start at low dose, e.g. 100mg od/bd, and ↑ dose over weeks until symptoms are controlled. Usual dose ≈200–400mg tds. Oxcarbazine is an alternative
Pregabalin Start with 75mg bd. Increase as needed to a maximum of 300mg bd. If ineffective, consider combining with amitriptyline
Amitriptyline Start at a dose of 25mg at 5–7 p.m.—10mg if elderly. ↑ dose by 10–25mg every 5–7d to a maximum of 75mg in a single dose as needed. Consider combining with pregabalin if ineffective alone
Refer to neurology if
<50y; neurological deficit between attacks; treatment with first-line agents fails—specialist options include lamotrigine, duloxetine, baclofen, phenytoin, or surgical intervention.
Further information
Headaches in young people and adults (2012)
Patient information and support
Organization for the Understaning of Cluster Headaches (OUCH UK) 01646 651 979
www.ouchuk.org
Trigeminal Neuralgia Association UK 01883 370214
www.tna.org.uk
Raised intracranial pressure
Raised intracranial pressure (↑ ICP) usually presents with increasing headache associated with drowsiness, listlessness, vomiting, focal neurology, and/or seizures. Causes include: 1° or 2° tumours, head injury, intracranial haemorrhage, hydrocephalus, meningitis, encephalitis, brain abscess, and cerebral oedema (2° to tumour, trauma, infection, ischaemia).
If suspected, admit as an emergency.
Drowsiness
↓ conscious level
Irritability
VI nerve palsy
Papilloedema
Dropping pulse
Rising BP
Focal neurological signs—due to underlying pathology
Pupil changes—constriction, then dilatation
Benign intracranial hypertension
Symptoms/signs of a space-occupying lesion, but none is found. Usually occurs in young, obese women. Cause unknown. Treated with repeat lumbar puncture, ventriculo-peritoneal shunt, diuretics, or dexamethasone. Usually resolves—but 10% recur later.
Brain abscess
May be single or multiple. Organisms reach the brain via the blood stream, direct implantation, or local extension from adjacent sites (e.g. sinusitis). Presents with ↑ ICP, focal neurological signs, systemic effects of infection, and/or local effects due to the cause. Usually, features develop over 2–3 wk—occasionally, more slowly; in the immunosuppressed, onset is rapid. If suspected, admit as an emergency. Treatment is with IV antibiotics ± surgical drainage. Mortality is 20–30%. 50% of survivors have long-term neurological deficit; 30% epilepsy.
Intracranial tumours
1˚ tumours 70%. Classified by whether they are benign/malignant and cell type. Glioma is an umbrella term meaning tumour of nervous system origin. Common subtypes: astrocytoma, oligodendroglioma, glioblastoma multiforme, and ependymoma. Tumours of the meninges (meningiomas) and cerebral blood vessels (cerebellar haemangioblastomas) can also occur.
2˚ brain tumours 30%—usually from carcinoma of breast, lung, or melanoma—in 50%, tumours are multiple
Presentation
<1% of patients with headache have a brain tumour.
↑ ICP 23–50% have papilloedema at presentation; headache 25–35%
Seizures 25–30%. Suspect in all adults who have a first seizure—especially if focal or with localizing aura. Refer for urgent assessmentN
Evolving focal neurology Depends on the site. >50% have focal neurology at presentation. Frontal lobe lesions tend to present late
False localizing signs Caused by ↑ ICP. VI nerve palsy (causing double vision) is most common due to its long intracranial course
Subtle personality change 16–20% at presentation—irritability, lack of application, lack of initiative, socially inappropriate behaviour
Local effects Skull base masses, proptosis, epistaxis
Differential diagnosis
Stroke, MS, head injury, vasculitis, encephalitis, Todd’s palsy ( p. 574), metabolic/electrolyte disturbance, other causes of space-occupying lesion—aneurysm, abscess, chronic subdural haematoma, granuloma, cyst.
Prognosis
Gliomas all have <50% 5y survival. Depending on site, meningiomas and haemangioblastomas have better prognosis.

Patients in whom a brain tumour is suspected with:
Symptoms related to the CNS, including:
Progressive neurological deficit
New-onset seizures
Unilateral sensorineural deafness
Headaches
Mental changes
Cranial nerve palsy
Headaches of recent onset accompanied by features suggestive of raised intracranial pressure, e.g.:
Vomiting
Drowsiness
Posture-related headache
Pulse-synchronous tinnitus
or accompanied by other focal or non-focal neurological symptoms, e.g. blackout, change in personality, or memory
A new, qualitatively different, unexplained headache that becomes progressively severe
Suspected recent-onset seizures
In patients with rapid progression of:
Subacute focal neurological deficit
Unexplained cognitive impairment, behavioural disturbance or slowness, or a combination of these
Personality changes confirmed by a witness and for which there is no reasonable explanation even in the absence of the other symptoms and signs of a brain tumour
Or discussion with specialist for unexplained headaches of recent onset:
Present for ≥1 mo
Not accompanied by features suggestive of ↑ intracranial pressure
Hydrocephalus
Dilatation of the cerebral ventricles and accumulation of CSF. May be:
Communicating Due to ↓ reabsorption of CSF. Causes: post-meningitis; SAH (80% develop some degree of hydrocephalus); trauma; neoplastic infiltration in the subarachnoid space
Non-communicating CSF flow is blocked due to an obstruction within the ventricles. Due to congenital malformations, tumour, brain abscesss, SAH, meningeal scarring due to meningitis, or cranial trauma
Presentation and management
In infants presents with macrocephaly ( p. 893); convulsions; developmental delay; and/or spasticity. In adults presents with ↑ ICP. Refer for urgent neurological assessment.
All patients with a CSF shunt should have pneumococcal vaccination.
Further information
NICE Referral guidelines for suspected cancer (2005) www.nice.org.uk
Information and support for patients
Brain & Spine Foundation 0808 808 1000
www.brainandspine.org.uk
Intracranial bleeds
Haemorrhagic stroke
p. 562
Subarachnoid haemorrhage (SAH)
Spontaneous bleeding into the subarachnoid space. Incidence 15/100,000. ♀ > ♂. Peak age 35–65y. Frequently fatal. Causes:
No cause (15%)
Rupture of congenital berry aneurysm (70%)
Bleeding disorder
Mycotic aneurysm 2° to endocarditis (rare)
Arteriovenous malformation (15%)
Risk factors
Smoking, alcohol, ↑ BP, less common pre-menopause. Berry aneurysms may run in families and are associated with polycystic kidneys, coarctation of the aorta, and Ehlers–Danlos syndrome.
Presentation
Typically presents as a sudden devastating headache—‘thunderclap headache’—often occipital
Rarely (6%) preceded by a ‘sentinel headache’ representing a small leak ahead of a larger bleed
Vomiting and collapse with loss of consciousness ± fitting ± focal neurology follow
Examination
May be nothing to find initially. Neck stiffness takes 6h to develop. In later stages:
Papilloedema
Retinal and other intraocular haemorrhages
Focal neurology
↓ level of consciousness
Action
If suspected admit immediately as a medical emergency. Only 1 in 4 admitted with suspected SAH turn out to have one. In most no cause for the headache is found.
Subdural haemorrhage
Bleeding is from bridging veins between cortex and venous sinuses, resulting in accumulation of blood between dura and arachnoid. Causes: trauma (may be trivial); idiopathic.
Risk factors
Age, alcohol, falls, epilepsy, anticoagulant therapy.
Presentation
Often insidious and history may go back several weeks:
Fluctuation of conscious level (35%)
Physical and intellectual slowing
Sleepiness
Headache
Personality change
Unsteadiness on feet
Slowly evolving stroke (e.g. hemiparesis)
Symptoms/signs of ↑ ICP
Differential diagnosis
Stroke, cerebral tumour, dementia.
Action
If suspected, admit as a medical emergency for further investigation. Evacuation of clot is possible even in very elderly patients and often results in full recovery.
Extradural haemorrhage
Blood accumulated between the dura and bone of the skull. Usually occurs after head injury.
Presentation
Deterioration of level of consciousness after head injury that initially produced no loss of consciousness or after initial post-injury drowsiness has resolved. This ‘lucid’ interval may last anything from a few hours to a few days. May be accompanied by worsening headache, vomiting, confusion ± focal neurological signs.
Action
If suspected, admit as an emergency for further investigation. Early evacuation of clot carries excellent prognosis. Outlook is less good if coma pre-op.
Acute stroke
Clinical syndrome typified by rapidly developing signs of focal or global disturbance of cerebral functions, lasting >24h or leading to death, with no apparent causes other than of vascular origin. Common and devastating condition—most common cause of adult disability in the UK. Half of all strokes occur in people >70y.
Causes
Cerebral infarction (~70%). Atherothrombotic occlusion or embolism. Sources of embolism: left atrium (AF) or left ventricle (MI or heart failure). Ischaemia causes direct injury from lack of blood supply
Intracerebral or subarachnoid haemorrhage (~19%). Haemorrhage causes direct neuronal injury and pressure exerted by the blood results in adjacent ischaemia
Rare causes Sudden ↓ BP, vasculitis, venous-sinus thrombosis, carotid artery dissection
Risk factors
Age
↑ BP
DM
AF
Previous stroke or TIA
MI
Artificial heart valves
Hyperviscosity syndromes
Smoking
Alcohol
Obesity
Low physical activity
Presentation
History Sudden onset of CNS symptoms or stepwise progression of symptoms over hours or days
Examination Conscious level—may be ↓ or normal; neurological signs (including dysphagia and incontinence); BP; heart rate and rhythm; heart murmurs; carotid bruits; systemic signs of infection or neoplasm
Differential diagnosis
Decompensation after recovery from previous stroke (e.g. due to infection, metabolic disorder); SOL—1° or 2° cerebral neoplasm; cerebral abscess; trauma—subdural haematoma, traumatic brain injury; epileptic seizure; migraine; MS.
Admit all patients who have suffered an acute stroke to hospital. Treatment of stroke in a stroke unit ↓ mortality and morbidityC. Thrombolysis early after stroke results in better outcome, so do not delay referral until the patient is seen. If stroke is suspected admit directly to hospital by emergency ambulance.
Do not give aspirin prior to admission.
Transient ischaemic attack (TIA)
History is as for stroke but recovery takes place within 24h of initial symptoms. Patients with a history of TIA have a 20% risk of stroke in the following month with highest risk in the first 72h. Risk can be predicted using the ABCD2 scoring system (see Table 16.9).
ABCD2 . | Feature . | Score . |
---|---|---|
Age | <60y | 0 |
≥60y | 1 | |
BP | Systolic ≥140 and/or diastolic ≥90 | 1 |
Clinical features | Unilateral weakness | 2 |
Speech disturbance without weakness | 1 | |
Other | 0 | |
Duration | ≥1h | 2 |
10–59min | 1 | |
<10min | 0 | |
Diabetes | Patient is diabetic | 1 |
Patient is not diabetic | 0 |
ABCD2 . | Feature . | Score . |
---|---|---|
Age | <60y | 0 |
≥60y | 1 | |
BP | Systolic ≥140 and/or diastolic ≥90 | 1 |
Clinical features | Unilateral weakness | 2 |
Speech disturbance without weakness | 1 | |
Other | 0 | |
Duration | ≥1h | 2 |
10–59min | 1 | |
<10min | 0 | |
Diabetes | Patient is diabetic | 1 |
Patient is not diabetic | 0 |
Scoring: High risk: 6–7 points—8.1% 2-day risk of stroke (21% of patients)
Medium risk: 4–5 points—4.1% 2-day risk of stroke (45% of patients)
Low risk: 0–3 points—1% 2-day risk of stroke (34% of patients)
Management of TIA
Admit if >1 TIA in <1wk. Consider admission/specialist assessment in <24h if the patient falls into a high/medium-risk group
If not admitting, once all symptoms have stopped, start aspirin 75mg od. Check blood for FBC, ESR, U&E, Cr, eGFR, lipids, and glucose. Consider clotting screen ± thrombophilia screening if FH of thrombosis. Check ECG and CXR
Start treatment for risk factors, e.g. advise to stop smoking, start antihypertensives if ↑ BP, start statin and dipyridamole S/R 200mg bd
Refer for urgent assessment (to be seen in <1wk) and further investigation to a specialist service, e.g. TIA clinic. Specialist investigations include: CT or MRI scan to confirm diagnosis, carotid Dopplers if carotid artery territory symptoms; echocardiogram if recent MI, CCF/LVF, or murmur
Amaurosis fugax
Form of TIA due to emboli passing through the retina. This causes brief loss of vision for a matter of minutes ‘like a curtain’. Management is as for TIA.
Subarachnoid haemorrhage
p. 560
Secondary prevention of stroke
p. 564
Rehabilitation
Further information
Royal College of Physicians National clinical guideline for stroke (2008) www.rcplondon.ac.uk
NICE Stroke: Diagnosis and initial management of acute stroke and TIA (2008) www.nice.org.uk
Patient information and support
Stroke Association 0303 3033 100
www.stroke.org.uk
Different Strokes 0845 130 7172
www.differentstrokes.co.uk
Speakability 0808 808 9572
www.speakability.org.uk
Secondary prevention of stroke
After stroke
Stroke is a family illness. 40% carers suffer psychological distress starting <6wk after discharge. Involve carers/families. Provide information/support. Address psychosocial issues and physical disability.
Monitor and reassess frequently. Continue follow-up even when specialist services have finished. Monitor 2° prevention measures. Refer for more specialist rehabilitation if there is any deterioration in function
Aids/appliances can help. Patients/carers may be entitled to benefits
After stroke most patients are prescribed ≥1 drugs to ↓ risk of further stroke, but some have memory loss or problems opening containers. Provide verbal and written information about medicines and help with packaging, e.g. non-childproof tops
Screening for depression
Patients with AF Use the CHA2DS 2-VASc score (Table 16.10) to predict stroke risk and need for anticoagulation if non-valvular AF, atrial flutter, or high risk of recurrence after cardioversion.
. | Condition . | Points . | Score . |
---|---|---|---|
C | Congestive heart failure | 1 | 0—Low risk—no antithrombotic therapy 1—Moderate risk—consider oral anticoagulation for men only ≥2—High risk—oral anticoagulation unless contraindicated Target INR for warfarin: 2–3 Do not withhold anticoagulation just because risk of falling |
H | Hypertension | 1 | |
A | Age >75y | 2 | |
A | Age 65–74y | 1 | |
D | DM | 1 | |
S | Female* | 1 | |
S | Prior stroke/TIA | 2 | |
VASc | Vascular disease e.g. MI, peripheral arterial disease, aortic plaque | 2 |
. | Condition . | Points . | Score . |
---|---|---|---|
C | Congestive heart failure | 1 | 0—Low risk—no antithrombotic therapy 1—Moderate risk—consider oral anticoagulation for men only ≥2—High risk—oral anticoagulation unless contraindicated Target INR for warfarin: 2–3 Do not withhold anticoagulation just because risk of falling |
H | Hypertension | 1 | |
A | Age >75y | 2 | |
A | Age 65–74y | 1 | |
D | DM | 1 | |
S | Female* | 1 | |
S | Prior stroke/TIA | 2 | |
VASc | Vascular disease e.g. MI, peripheral arterial disease, aortic plaque | 2 |
For women <65y with no other risk factors, CHA2DS2-VASc score = 0
In all cases weigh benefit of treatment against potential harms. The HAS-BLED score may help with decision-making:
Hypertension (uncontrolled, systolic >160mmHg)—1 point
Abnormal liver function (cirrhosis, bilirubin >2x normal, ALT/AST/alk phos >3x normal)—1 point
Abnormal renal function (dialysis, Cr >200micromol)—1 point
Stroke history—1 point
Prior major bleed or predisposition to bleeding—1 point
Labile INR (<60% of the time in therapeutic range)—1 point
Elderly (age ≥65y)—1 point
Drugs predisposing to bleeding (e.g. antiplatelet agents, NSAIDs)—1 point
Harmful alcohol use—1 point
A score ≥3 indicates ↑ 1-year bleed risk on anticoagulation sufficient to justify caution before prescribing or more regular review
p. 199
Secondary stroke prevention
Patients with a history of stroke or TIA/amaurosis fugax have a 30–43% risk of recurrent stroke in <5y. Prevention focusses on ischaemic/embolic events which account for the majority of strokes. Preventative strategies include:
Lifestyle advice
Antiplatelet drugs
Start patients not taking warfarin, who have had a non-haemorrhagic stroke on CT/MRI on clopidogrel 75mg od long-termN (aspirin 75mg od + dipyridamole S/R 200mg bd if intolerant). For patients who have had a TIA start aspirin 75mg od + dipyridamole S/R 200mg bd (dipyridamole M/R 200mg bd alone if intolerant to aspirin).
Oral anticoagulation
For 1° and 2° stroke prevention, anticoagulate with warfarin or a novel anticoagulant if potential causes of cardiac thromboembolism, e.g. rheumatic mitral valve disease; prosthetic heart valves; dilated cardiomyopathy; or AF associated with valvular heart disease or prosthesis or with CHA2DS2-VASc score ≥ (consider ≥ if ♂)
Hypertension management
p. 248
Systolic and diastolic BP independently predict stroke. Risk escalates with increasing BP. A 5–6mmHg ↓ BP reduces risk by >30%
After stroke (but not after TIA) defer treating hypertension until >2wk after the event as ↑ BP may be physiological response—lowering BP decreases perfusion of the brain and may be harmful
Cholesterol
Primary prevention A 22% ↓ in cholesterol using a statin results in a 30%↓ in stroke in individuals with no past history of stroke/TIA. Treat if patients meet criteria for coronary prevention ( p. 242)
Secondary prevention Treat all patients with a history of CVD with a statin regardless of baseline cholesterol. National Stroke Guidelines suggest treatment with a statin, e.g. simvastatin 40mg od, if total cholesterol is >3.5mmol/L unless contraindicated
Carotid stenosis and carotid endarterectomy
Carotid endarterectomy ↓ mortality if carotid stenosis is symptomatic. Benefits ↓ as stenosis gets less—no evidence of benefit if <30% stenosis.
Patients without history of stroke/TIA 2% annual risk of stroke so surgery is controversial—in general risks outweigh benefits
Patients with a history of stroke /TIA Consider referral for carotid endarterectomy/carotid artery stenting if >70% carotid artery stenosis and no severe disability
Further information
Royal College of Physicians National clinical guidelines for stroke (2012) www.rcplondon.ac.uk
NICE Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (2010) www.nice.org.uk
Atrial fibrillation: the management of atrial fibrillation (2014)
Patient information and support
Stroke Association 0303 3033 100
www.stroke.org.uk
Parkinsonism and Parkinson’s disease
Parkinsonism
Syndrome of:
Tremor Coarse tremor, most marked at rest, ‘pill-rolling’
Rigidity Limbs resist passive extension throughout movement—lead-pipe rigidity—and juddering on passive extension of the forearm or pronation/supination—cogwheel rigidity
Difficulty in initiating movement
Slowness of movement Mask-like or expressionless face, ↓ blink rate, ↓ fidgeting, ↓ peristalsis
Abnormal gait Small steps—shuffling gait—and flexed posture as if hurrying to keep up with feet—festinant gait
Micrographia Small handwriting
Causes
Parkinson’s disease (PD)
Other neurodegenerative diseases, e.g. Alzheimer’s disease, multisystem atrophy
Following encephalitis
Drugs, e.g. haloperidol, chlorpromazine, metoclopramide
Toxins, e.g. CO poisoning
Trauma
Normal pressure hydrocephalus
Treatment of drug-induced parkinsonism
If possible, stop the implicated drug. If on an antipsychotic for schizophrenia do not stop treatment, but add an antimuscarinic (e.g. procyclidine 2.5mg tds). Consider switching to an atypical antipsychotic drug—take specialist advice.
Steele–Richardson–Olszewski syndrome
Parkinsonism accompanied by absent vertical gaze and dementia. Due to progressive supranuclear palsy. J.C. Steele, J.C. Richardson, and J. Olszewski—Canadian neurologists.
Parkinson’s disease (PD)
Incurable, progressive, degenerative disease affecting the dopaminergic neurones of the substantia nigra in the brainstem, resulting in deficiency of dopamine and relative excess of acetylcholine transmitters. Cause: unknown. Lifetime risk: 1 in 40. ♂ = ♀. Peak age at onset: ≈65y, but 5–10% patients are diagnosed when <40y old. Prevalence ↑ with age. J. Parkinson (1755–1824)—English physician.
Non-motor symptoms
Neuropsychiatric—apathy, anxiety/depression, visual hallucinations, psychosis, dementia, pain, olfactory disturbance
Sleep—excessive daytime sleepiness, restless legs
Autonomic—drooling, postural hypotension, hyperhidrosis, urinary dysfunction, dysphagia, weight↓, constipation, sexual dysfunction
Management
Aims to:
↓ symptoms and ↑ quality of life
↓ rate of disease progression
Limit side effects of treatment
Screening for depression
p. 199
Referral
Refer all patients to a specialist with an interest in Parkinson’s disease for confirmation of diagnosis, advice on management, and to access a multidisciplinary specialist rehabilitation team.
Rehabilitation
Liaise closely with the specialist rehabilitation team.
Drug treatment
(BNF 4.9) Rarely achieves complete control of symptoms; 5–10% respond poorly. Treatment for PD should be consultant-initiated and is not started until symptoms cause significant disruption of daily activities. Options:
Dopamine receptor agonists
(e.g. bromocriptine, pergolide). Often used alone as first-line treatment. ↑ dose gradually, according to response and tolerability. Withdraw gradually. Can also be used in association with L-dopa to ↓ off times and motor impairment.
Bromocriptine, pergolide, cabergoline, and lisuride have been associated with pulmonary, retroperitoneal, and pericardial fibrosis.
Check CXR ± spirometry, ESR, and creatinine before starting
Monitor for dyspnoea, persistent cough, chest pain, cardiac failure, abdominal pain, or tenderness
Levodopa (or L-dopa)
Precursor of dopamine. ↑ dopamine levels within the substantia nigra. Start with low dose and ↑ in small steps—aim to keep final dose as low as possible and a compromise between ↑ mobility and dose-limiting side effects (involuntary movements, psychiatric effects). Optimum dose interval varies between individuals.
Only effective for PD. Not effective for patients with parkinsonism due to other causes. Improves bradykinesia and rigidity > tremor
Often given with a co-drug (carbidopa or benserazide) which prevents peripheral breakdown of levodopa to dopamine but does not cross the blood–brain barrier
With time, there is ↓ response and troublesome side effects appear:
On-off effect—fluctuation between periods of exaggerated involuntary movements and periods of immobility
End-of-dose effect—duration of benefit after each dose reduces
Abnormal involuntary movements ↑
Other drugs
Monoamine oxidase B inhibition (e.g selegiline, rasagaline). Used in severe PD in conjunction with levodopa to ↓ end-of-dose effect. Early use may postpone onset of treatment with levodopa
Amantadine Improves bradykinesia, dyskinesias, tremor, and rigidity. Introduce and withdraw slowly
Inhibition of enzymatic breakdown of dopamine (e.g. entacapone, tolcapone). For patients suffering from end-of-dose effect
Surgery
A small proportion of carefully selected patients benefit from ‘deep brain stimulation’ (DBS).
Driving
p. 130
Carers
p. 220
Further information
NICE Parkinson’s disease: diagnosis and management in primary and secondary care (2006) www.nice.org.uk
Patient advice and support
Parkinson’s Disease Society 0808 800 0303
www.parkinsons.org.uk
Multiple sclerosis
Multiple sclerosis (MS) is a chronic disabling neurological disease due to an autoimmune process of unknown cause. Characterized by formation of patches of demyelination (‘plaques’) throughout the brain and spinal cord. There is no peripheral nerve involvement.
It is the most common neurological disorder of young adults, with a lifetime risk of 1:1,000. Peak age of onset is 20–40y. ♀:♂ ≈2:1. There is a marked geographical variation—prevalence ↑ with latitude.
Presentation
Depends on the area of CNS affected. Take a careful history—although a patient usually presents with a single symptom, history may reveal other episodes that have gone unheralded. Isolated neurological deficits are never diagnostic. The hallmark of MS is a series of neurological deficits distributed in time and space not attributable to other causes. Predominant areas of demyelination are optic nerve, cervical cord, and periventricular areas.
Common features
Pain on eye movement (optic neuritis)
Visual disturbance— ↓, blurring, or double vision
↓ balance and coordination
Sensory disturbance (e.g. numbness, tingling)
Pain (e.g. trigeminal neuralgia)
Fatigue
Depression
Transverse myelitis ( p. 572)
Problems with speech (e.g. slurred or slow)
Bladder problems (e.g. frequency, urgency, incontinence)
Constipation
Sexual dysfunction (e.g. impotence)
Cognitive changes (e.g. loss of concentration, memory problems)
Dysphagia
Symptoms may be worsened by heat or exercise.
Prognosis
Benign MS (10%). Retrospective diagnosis. The patient has a few mild attacks and then complete recovery. There is no deterioration over time and no permanent disability
Relapsing-remitting MS (RRMS) 85% patients. Episodes of sudden ↑ in neurological symptoms or development of new neurological symptoms with virtually complete recovery after 4–6wk. With time remissions become less complete and residual disability accumulates
Secondary progressive MS (SPMS) After ~15y, 65% of patients with relapsing-remitting disease begin a continuous downward progression which may also include acute relapses
Primary progressive MS (PPMS) 10% patients. Steady progression from the outset with increasing disability
Management
If suspected, refer to neurology for confirmation of diagnosis and support from the specialist neurological rehabilitation team.
Disease-modifying drugs
↓ frequency and/or severity of relapses by ~30% and slow course of the disease. Options are β-interferon (for RRMS and SPMS), and glatiramer (for RRMS only). Prescription must be consultant-led under the NHS risk-sharing scheme—Table 16.11.
. | β-interferon . | Glatiramer . |
---|---|---|
Age | ≥18y | ≥18y |
Contraindications | No contraindications present | No contraindications present |
Walking distance | RRMS Can walk ≥100m without assistance SPMS Can walk ≥10m without assistance | RRMS Can walk ≥100m without assistance |
Relapses | RRMS ≥2 clinically significant relapses in the last year SPMS Minimal ↑ in disability due to gradual progression and ≥2 disabling relapses in the past 2y | RRMS ≥2 clinically significant relapses in the last year |
Stop if | • Intolerable side effects • Pregnant/planning pregnancy • ≥2 disabling relapses in <1y • Inability to walk (± assistance) persisting ≥6mo • 2° progression with observable ↑ in disability over 6mo | • Intolerable side effects • Pregnant or planning pregnancy • ≥2 disabling relapse in <1y • Inability to walk (± assistance) persisting ≥6mo • 2° progression |
. | β-interferon . | Glatiramer . |
---|---|---|
Age | ≥18y | ≥18y |
Contraindications | No contraindications present | No contraindications present |
Walking distance | RRMS Can walk ≥100m without assistance SPMS Can walk ≥10m without assistance | RRMS Can walk ≥100m without assistance |
Relapses | RRMS ≥2 clinically significant relapses in the last year SPMS Minimal ↑ in disability due to gradual progression and ≥2 disabling relapses in the past 2y | RRMS ≥2 clinically significant relapses in the last year |
Stop if | • Intolerable side effects • Pregnant/planning pregnancy • ≥2 disabling relapses in <1y • Inability to walk (± assistance) persisting ≥6mo • 2° progression with observable ↑ in disability over 6mo | • Intolerable side effects • Pregnant or planning pregnancy • ≥2 disabling relapse in <1y • Inability to walk (± assistance) persisting ≥6mo • 2° progression |
Natalizumab and fingolimod
Approved for treatment of highly active RRMS, despite treatment with β-interferon, or rapidly evolving severe RRMS. Prescription must be consultant-led.
Natalizumab Is associated with ↑ risk of opportunistic infection and progressive multifocal leucoencephalopathy (PML). If new/worsening neurological symptoms/signs refer to neurology immediately
Fingolimod Is associated with macular oedema in 0.4%; routine ophthalmological review is recommended 3–4mo after initiation
Acute relapses
Treat episodes causing distressing symptoms or ↑ limitation with high-dose steroids e.g. prednisolone 500mg–2g od po for 3–5d. Alternatively refer for high-dose IV steroids. Refer to specialist neurological rehabilitation if residual deficit or if frequent relapses.
Management of symptoms and disability
Liaise closely with the specialist neurological rehabilitation team.
Further information
NICE/RCP Diagnosis and management of multiple sclerosis in primary and secondary care (2003) www.nice.org.uk
MS Society A guide to MS for GPs and primary care professionals (2009) www.mssociety.org.uk
Patient advice and support
MS Society 0808 800 8000
www.mssociety.org.uk
Motor neurone disease and CJD
Motor neurone disease (MND)
Is a degenerative disorder of unknown cause affecting motor neurones in the spinal cord, brainstem, and motor cortex. Prevalence in the UK ~4.5/100,000 population ♂:♀ ≈3:2. Peak age of onset ≈60y. 10% have a FH. There is never any sensory loss.
Patterns of disease
There are 3 recognized patterns of MND:
Amyotrophic lateral sclerosis (ALS) (50%). Combined LMN wasting and UMN hyperreflexia
Progressive muscular atrophy (25%). Anterior horn cell lesions, affecting distal before proximal muscles. Better prognosis than ALS
Progressive bulbar palsy (25%). Loss of function of brainstem motor nuclei (LMN lesions), resulting in weakness of the tongue, muscles of chewing/swallowing, and facial muscles
Clinical picture
Combination of progressive upper and/or lower motor neurone signs, affecting >1 limb or a limb and the bulbar muscles. Symptoms and signs:
Stumbling (spastic gait, foot drop)
Tiredness
Muscle wasting
Weak grip
Weakness of skeletal muscles
Cramp
Fasciculation of skeletal muscles
Fasciculation of the tongue
Difficulty with speech (particularly slurring, hoarseness, or nasal or quiet speech)
Difficulty with swallowing
Aspiration pneumonia
MND never affects eye movements (cranial nerves III, IV, VI)
Management
Refer to neurology for exclusion of other causes of symptoms and confirmation of diagnosis. MND is incurable and progressive. Death usually results from ventilatory failure 3–5y after diagnosis.
Drug therapy
Riluzole (50mg bd) is the only drug treatment licensed in the UK
Evidence suggests it extends life or time to mechanical ventilation for patients with ALS. It may also slow functional declineN
It should be initiated by a specialist with experience of MNDN
Monitoring of liver function is essential—monthly for the first 3mo; then 3-monthly for 9mo; then annually thereafter
Support
Involve relevant agencies early, e.g. DN, social services, carer groups, self-help groups
Apply for all relevant benefits ( p. 222)
Screen for depression ( p. 199)
Discuss the future and patients’ wishes for the time when they become incapacitated with patient and carer(s)
Regular review to help overcome any new problems encountered is helpful for patients and carers
Symptom relief
Spasticity—baclofen, tizanidine, botulinum toxin
Drooling—propantheline 15–30mg tds po or amitriptyline 25–50mg tds
Dysphagia—blend food, discuss NG tubes/PEG ( p. 583)
Depression—common. Reassess support, consider drug treatment, and/or counselling
Joint pains—analgesia
Respiratory failure—discuss tracheostomy/ventilation; weigh pros and cons of prolongation of life versus prolongation of discomfort
Creutzfeldt–Jakob disease (CJD)
(human spongiform encephalopathy). Fatal, degenerative brain disease due to a rogue form of brain protein or ‘prion’. Types:
Sporadic or classical Most common form in the UK (~50 cases/y). Rare <40y. Median duration of symptoms 3–4 mo. Cause: unknown
Variant Affects younger people than classical CJD and duration is longer, lasting a median of 14mo. Cause: transmitted by ingestion of nervous tissue in beef infected with bovine spongiform encephalitis or ‘mad cow disease’. Compensation may be available to families
Iatrogenic Cases associated with treatments using human growth hormone and human dura mater grafts. Rarely associated with corneal grafts or contaminated instruments used in surgery
Familial prion disease ~20–30 families in the UK are affected with a version of CJD passed from generation to generation in an autosomal dominant pattern. Median duration of symptoms from onset is 2–5y
Presentation
Long incubation (>25y in some cases). Clinical features vary according to the areas of brain most affected but are always rapidly progressive. Common features: personality change; psychiatric symptoms; cognitive impairment; neurological deficits (sensory and motor deficits, ataxia); myoclonic jerks, chorea, or dystonia; difficulty with communication, mobility, swallowing, and continence; coma and death.
Differential diagnosis
Dementia, depression, MS, MND, SOL.
Management
General principles of rehabilitation
p. 204
Common neurological rehabilitation problems
p. 582
Further information
Riluzole for motor neurone disease (2004)
Motor neurone disease—non-invasive ventilation (2010)
Patient advice and support
Motor Neurone Disease Association 08457 626262
www.mndassociation.org
Brain and Spine Foundation 0808 808 1000
www.brainandspine.org.uk
Spinal cord conditions
Spinal cord injury tends to affect young people, especially young men. It is devastating, and the GP and primary care team are a vital part of the ongoing support network. Causes: trauma (42% falls; 37% RTAs), herniated disc, transverse myelitis, tumour, abscess.
Quadriplegia and tetraplegia
Caused by spinal cord injury above the first thoracic vertebra. Usually results in paralysis of all four limbs, weakened breathing, and an inability to cough and clear the chest.
Paraplegia
Occurs when the level of injury is below the first thoracic nerve. Disability can vary from the impairment of leg movement to complete paralysis of the legs and abdomen up to the nipple line. Paraplegics have full use of their arms and hands.
Incomplete spinal cord injuries
Anterior cord syndrome Damage is towards the front of the spinal cord, leaving the patient with loss or ↓ ability to sense pain, temperature, and touch sensations below the level of injury. Pressure and joint sensation may be preserved
Central cord syndrome Damage is in the centre of the spinal cord. Typically results in loss of function in the arms, but preservation of some leg movement ± some control of bladder/bowel function
Posterior cord syndrome Damage is towards the back of the spinal cord. Typically leaves patients with good muscle power, pain, and temperature sensation, but difficulty coordinating limb movements
Brown-Séquard syndrome Damage is limited to one side of the spinal cord resulting in loss or ↓ movement on the injured side but preserved pain and temperature sensation, and normal movement on the uninjured side but loss or ↓ in pain and temperature sensation. C.E. Brown-Séquard (1817–94)—French neurologist/physiologist
Cauda equina lesion
The spinal cord ends at L1/L2 at which point a bundle of nerves travels downwards through the lumbar and sacral vertebrae. Injury to these nerves causes partial or complete loss of movement and sensation. There may be some recovery of function with time.
Transverse myelitis
Inflammation of the spinal cord at a single level. Symptoms develop rapidly over days/weeks and include limb weakness, sensory disturbance, bowel and bladder disturbance, back pain, and radicular pain. Recovery generally begins within 3mo but is not always complete. Causes:
Idiopathic (thought to be auto-immune mechanism)
Infection
Vaccination
Autoimmune disease, e.g. SLE, Sjögren’s syndrome, sarcoidosis
MS
Malignancy
Vascular, e.g. thrombosis of spinal arteries, vasculitis 2° to heroin abuse, spinal A-V malformation
Management
Depending on severity of symptoms, admit as an acute medical emergency or refer for urgent neurological opinion.
Syringomyelia
Tubular cavities (syrinxes) form close to the central canal of the spinal cord. As the syrinx expands it compresses nerves within the spinal cord. Most common in patients with previous spinal injury—although may be years before. Typically presents with wasting and weakness of hands and arms, and loss of temperature and pain sensation over trunk and arms (cape distribution). Refer to neurology.
General principles of rehabilitation
p. 204
Common neurological rehabilitation problems
p. 582
Specific problems associated with spinal cord injury
Autonomic dysreflexia (hyperreflexia)
Reflex sympathetic overactivity, causing flushing and ↑ BP which may be severe. Only occurs in patients with lesions above T5/6. Usually triggered by discomfort below the level of the lesion. Presentation is with pounding headache, sweating, flushing, or mottling above the level of the lesion.
Sit the patient up and remove any obvious cause, e.g. pain, bladder distension, constipation. Give GTN spray (1–2 puff sublingual) or nifedipine 5–10mg capsule broken sublingually. If not settling, admit to hospital.
Loss of temperature control
Most people with complete spinal cord injuries do not sweat below the level of the injury and many quadriplegics cannot sweat above the injury (even though they may sweat due to autonomic dysreflexia). With loss of ability to sweat or vasoconstrict, careful control of environmental conditions is essential to avoid hypothermia or overheating. In hot weather advise cooling with wet towels.
Infertility
Many ♂ patients suffer infertility due to:
Failure of ejaculation
Retrograde ejaculation
Thermal damage due to sitting in a wheelchair → poor-quality sperm
Chronic infection of prostate and seminal vesicles (common)
Refer for specialist advice.
Bowel/bladder function
Both bladder and bowel function are reflex actions that we learn to override as children. If the lesion is above the level of this reflex pathway (T12 for bowel and T6 for bladder function) then automatic emptying will still occur when the bladder or bowel is full—though there is no control. If the lesion is below this level there is no emptying reflex. Bladder/bowel care programmes reflect this. Useful leaflets are available from the Spinal Injuries Association.
Spasticity
p. 583
UTI
p. 583
Pressure sores
p. 613
Depression
p. 199
Patient advice and support
Spinal Injuries Association 0800 980 0501
www.spinal.co.uk
Brain and Spine Foundation 0808 808 1000
www.brainandspine.org.uk
Transverse Myelitis Society www.myelitis.org.uk
British Syringomyelia & Chiari Society www.britishsyringomyelia-chiarisociety.org
Epilepsy
Epilepsy is a group of disorders in which fits or seizures occur as a result of spontaneous abnormal electrical discharge in any part of the brain. They take many forms but usually take the same pattern on each occasion for a given individual. Prevalence 5–10/1,000. 5% of those >21y old having their first fit have cerebral pathology (10% aged 45–55y).
Epilepsy in children
p. 898
Management of a fitting patient/status epilepticus
p. 1070
Management after first fit
60% of adults who have one fit will never have another (90% if EEG is normal).
Refer all patients with a first suspected seizure for urgent (within 2wk) assessment by a neurologist with training and expertise in epilepsy to exclude underlying causes (e.g. tumour) and receive clear guidance on medication, work, and driving N.
Classification of seizure types
Is important, as these have implications for management and prognosis.
Partial seizures The seizure is limited to one area of the brain only. Termed ‘simple’ if no impairment of consciousness (previously called focal or Jacksonian epilepsy) and ‘complex’ if consciousness is impaired (previously called psychomotor or temporal lobe epilepsy). Partial seizures may become generalized
Generalized seizures Whole brain is involved. Consciousness is usually but not always impaired. 6 major types: tonic-clonic (grand mal); absence (petit mal); myoclonic; tonic; clonic; and atonic
Some people have seizures that cannot be classified in this way.
Todd’s palsy
Focal CNS signs (e.g. hemiplegia) following an epileptic seizure. The patient seems to have had a stroke but recovers in <24h.
Causes of epilepsy in adults
A cause is found in more than two-thirds of people with epilepsy. The most common causes are:
Cerebrovascular disease
Cerebral tumours
Genetic, congenital, or hereditary conditions
Drugs, alcohol, and other toxic causes
Head trauma (including surgery)
Post-infective causes (e.g. meningitis, encephalitis)
Assessment
See Table 16.12.
History . | . |
---|---|
Background | • Previous head injury • Alcohol/drug abuse • Meningitis or encephalitis • Stroke • Febrile convulsions • Family history of epilepsy |
Provoking factors | • Sleep deprivation • Alcohol withdrawal • Flashing lights |
Prodrome/aura | Prodrome—precedes fit. May be a change in mood or behaviour noticed by the patient or others Aura—part of the seizure that precedes other manifestations; odd sensations, e.g. déjà vu (odd feeling of having experienced that time before), strange smells, rising abdominal sensation, flashing lights |
Features of the attack | Eye witness report: if available—colour of the patient, movement, length of fit, circumstances, after-effects Memories of the patient: memories of the event and/or first memories after the event, frequency of attacks, relationship to sleep, menses, etc. |
Residual symptoms after the attack | • Bitten tongue • Incontinence of urine/faeces (not specific for epilepsy) • Confusion • Headache • Aching limbs or temporary weakness of limbs (Todd’s palsy) |
Examination | |
Neurological examination | • Fever, photophobia, neck stiffness, or petechial rash? • Any residual deficit • Focal neurology • Signs of ↑ ICP ( |
General examination | • BP, heart sounds, heart rhythm and rate • Signs of systemic illness |
Investigations (first fit only) | • ECG • Blood for U&E, Cr, eGFR, LFT, Ca2+, FBC, ESR/CRP |
Differential diagnosis • Vasovagal syncope • Psychogenic non-epileptic attacks (pseudo-seizures) • Tics • Panic attack • Hypoglycaemia • Normal phenomenon (e.g. déja vu) • Cardiac arrhythmias • Other cardiac disorders (e.g. aortic stenosis, HOCM) • TIA • Migrainous aura |
History . | . |
---|---|
Background | • Previous head injury • Alcohol/drug abuse • Meningitis or encephalitis • Stroke • Febrile convulsions • Family history of epilepsy |
Provoking factors | • Sleep deprivation • Alcohol withdrawal • Flashing lights |
Prodrome/aura | Prodrome—precedes fit. May be a change in mood or behaviour noticed by the patient or others Aura—part of the seizure that precedes other manifestations; odd sensations, e.g. déjà vu (odd feeling of having experienced that time before), strange smells, rising abdominal sensation, flashing lights |
Features of the attack | Eye witness report: if available—colour of the patient, movement, length of fit, circumstances, after-effects Memories of the patient: memories of the event and/or first memories after the event, frequency of attacks, relationship to sleep, menses, etc. |
Residual symptoms after the attack | • Bitten tongue • Incontinence of urine/faeces (not specific for epilepsy) • Confusion • Headache • Aching limbs or temporary weakness of limbs (Todd’s palsy) |
Examination | |
Neurological examination | • Fever, photophobia, neck stiffness, or petechial rash? • Any residual deficit • Focal neurology • Signs of ↑ ICP ( |
General examination | • BP, heart sounds, heart rhythm and rate • Signs of systemic illness |
Investigations (first fit only) | • ECG • Blood for U&E, Cr, eGFR, LFT, Ca2+, FBC, ESR/CRP |
Differential diagnosis • Vasovagal syncope • Psychogenic non-epileptic attacks (pseudo-seizures) • Tics • Panic attack • Hypoglycaemia • Normal phenomenon (e.g. déja vu) • Cardiac arrhythmias • Other cardiac disorders (e.g. aortic stenosis, HOCM) • TIA • Migrainous aura |
Screening for depression
p. 199
Long-term management of epilepsy
p. 576
Epilepsy and pregnancy
p. 829
Mortality
Death rate is ↑ x2–3. Deaths are related to underlying condition, accidents, SUDEP, or status epilepticus.
Sudden unexplained death in epilepsy (SUDEP)
Probably due to central respiratory arrest during a seizure. Minimize risk by optimizing seizure control and being aware of potential consequences of night seizures.
Further information
Patient advice and support
Epilepsy Action 0808 800 5050
www.epilepsy.org.uk
Management of epilepsy
Regular GP review, at least annually, is essential.
Education
Epilepsy is a diagnosis causing alarm and fear. Find out how much the patient (and family) understands about epilepsy. Acknowledge distress at diagnosis and answer their questions. Provide information on:
What to expect—fits are controlled with drugs in 80%
What to do during an attack
Driving ( p. 130) and work—stop driving, and notify DVLA and motor insurance company. Inform employer. Do not work at heights or with/near dangerous machinery
Avoiding risks—avoid cycling in traffic; only swim if lifeguard present
Importance of concordance with medication
When drug withdrawal may be considered if fit-free
Leaflets are available from Epilepsy Action. Support groups can help.
Drug therapy
BNF 4.8.1. NICE recommends drug treatment (see Table 16.13) after the second seizure, except in specific circumstances. Drug choice is a specialist decision. Patients on anticonvulsants are entitled to free prescriptions throughout the UK.
. | . | Ethosuximide . | Sodium valproate . | Carbamazepine . | Lamotrigine . | Clonazepam . |
---|---|---|---|---|---|---|
Type of epilepsy | Absence | ✓ | ✓ | ✓ | ✓ | |
Myoclonic | ✓ | ✓ | ||||
Tonic clonic | ✓1 | ✓ | ✓ | |||
Partial ± 2° generalized | ✓ | ✓ | ✓ | |||
Adult starting dose | 500mg od | 300mg bd | 100–200mg od or bd | 25mg od for 2wk2 | 1mg nocte for 4d | |
Incremental dose | 250mg/d at weekly intervals | 200mg/d at 3-day intervals | 100mg/d at weekly intervals | From starting dose to 50mg od for 2wk, then ↑ by 50mg/d at weekly intervals | ↑ according to response over 2–4wk | |
Usual daily dose | 1–1.5g od | 500mg–1g bd | 200–1200mg | 100–200mg | 4–8mg nocte | |
Common/important side effects | Blood dyscrasias3, sedation, nausea, vomiting, dizziness, ataxia | Pancreatitis, liver toxicity4, blood dyscrasias3, sedation, tremor, weight ↑, hair thinning, ankle swelling | Blood dyscrasias3, rash, liver toxicity4, nausea, sedation, diplopia, dizziness, fluid retention, ↓ Na+ 5 | Blood dyscrasias3, rash, fever, influenza-like symptoms, drowsiness, or worsening of seizure control | Drowsiness/fatigue, amnesia/confusion/restlessness, muscle hypotonia, co-ordination problems, dependence, and withdrawal |
. | . | Ethosuximide . | Sodium valproate . | Carbamazepine . | Lamotrigine . | Clonazepam . |
---|---|---|---|---|---|---|
Type of epilepsy | Absence | ✓ | ✓ | ✓ | ✓ | |
Myoclonic | ✓ | ✓ | ||||
Tonic clonic | ✓1 | ✓ | ✓ | |||
Partial ± 2° generalized | ✓ | ✓ | ✓ | |||
Adult starting dose | 500mg od | 300mg bd | 100–200mg od or bd | 25mg od for 2wk2 | 1mg nocte for 4d | |
Incremental dose | 250mg/d at weekly intervals | 200mg/d at 3-day intervals | 100mg/d at weekly intervals | From starting dose to 50mg od for 2wk, then ↑ by 50mg/d at weekly intervals | ↑ according to response over 2–4wk | |
Usual daily dose | 1–1.5g od | 500mg–1g bd | 200–1200mg | 100–200mg | 4–8mg nocte | |
Common/important side effects | Blood dyscrasias3, sedation, nausea, vomiting, dizziness, ataxia | Pancreatitis, liver toxicity4, blood dyscrasias3, sedation, tremor, weight ↑, hair thinning, ankle swelling | Blood dyscrasias3, rash, liver toxicity4, nausea, sedation, diplopia, dizziness, fluid retention, ↓ Na+ 5 | Blood dyscrasias3, rash, fever, influenza-like symptoms, drowsiness, or worsening of seizure control | Drowsiness/fatigue, amnesia/confusion/restlessness, muscle hypotonia, co-ordination problems, dependence, and withdrawal |
Drug of choice for primary syndromes of generalized epilepsy.
Starting dose is different if used in association with other epileptics—see BNF.
Check FBC if bruising, mouth ulcers, or symptoms of infection (sore throat, fevers).
Warn about symptoms of liver disease. Check LFTs soon after starting and at review.
Monitor U&E at regular review.
Withdrawal of drug therapy
Consider if fit-free for 2–3y. Decision to stop must be the patient’s. Balance problems/inconvenience of drug- taking against risks of fits. Refer to neurology for supervision of drug withdrawal. If adult with grand mal epilepsy, 59% stay fit-free for 2y.
Seizure recurrence is more likely if
generalized tonic-clonic seizures; myoclonic epilepsy or infantile spasms; taking >1 drug for epilepsy; ≥1 seizure after starting treatment; duration of treatment >10y; fit-free <5y.
Advise patients not to drive during withdrawal of epileptic medication or for 6mo afterwards.
Surgery
Used for intractable partial seizures, hemiepilepsy, and epilepsy with focal EEG and/or radiological features.
Vagus nerve stimulation
↓ frequency of seizures for those refractory to anti-epileptic medication but not suitable for resective surgery.
Ketogenic diet
Effective in some patients with refractory epilepsy—take specialist advice.
At review
Review the individual’s care plan. Record fits and precipitating causes; check drug concordance (frequency of repeat prescriptions) and side effects; if fit-free >2y—discuss the possibility of withdrawing medication, if appropriate. For women of reproductive age give contraception ( p. 756) and pre-conception advice (
p. 829).
Re-refer
For review by a neurologist or epilepsy nurse specialist if:
Control is poor or drugs are causing unacceptable side effects
Seizures have continued despite medication for >2y or on two drugs
Pointers to a previously unsuspected cause for the fits appear
Concurrent illness (physical or psychiatric) complicates management
For pre-conceptual advice or to discuss withdrawal of medication
Muscle disorders
Symptoms
Muscle weakness, fatigability. Pain at rest suggests inflammation—pain on exercise, ischaemia, or metabolic myopathy.
Signs
Look for associated systemic disease.
Myotonia—delayed muscular relaxation after contraction, e.g. difficulty letting go after gripping something
Local muscular tenderness or firm muscles—may be due to infiltration of muscle with connective tissue or fat
Fasciculation—spontaneous, irregular, and brief contractions of part of a muscle; suggests LMN disease, e.g. MND
Lumps—tumours are rare; lumps may be due to tendon rupture, haematoma, or herniation of muscle through fascia
Muscular dystrophies
Group of genetic disorders characterized by progressive degeneration and weakness of some muscle groups.
Myotonic dystrophy (dystrophia myotonia)
Autosomal dominant inheritance—abnormal DMPK gene on chromosome 19. Presents at any age. Symptoms vary from mild to severe and may include:
Muscle symptoms—weakness and myotonia, particularly involves face, eyelids, jaw, neck, forearms/hands, lower legs/feet. Can affect speech and result in a lack of facial expression
Respiratory symptoms—weakness of respiratory muscles → poor night-time sleep, daytime sleepiness, headaches, and difficulty waking; aspiration → recurrent chest infections
Eye symptoms—cataract (may be the only problem) and ptosis
Reproductive problems—infertility as a result of atrophy of the testes and problems in labour due to uterine muscle weakness
Learning difficulty and behavioural problems
Digestive symptoms—swallowing difficulty, abdominal pain, constipation/diarrhoea, gallstones
Cardiac arrhythmias—annual ECG is advisable
Endocrine abnormalities, e.g. DM
Anaesthetic problems—pre-warn anaesthetist/surgeon prior to surgery
Prognosis is variable depending on severity of symptoms. Refer to confirm diagnosis and for advice on management/genetic counselling.

Sex-linked recessive inheritance means almost always confined to boys. 30% of cases are due to spontaneous mutation. Investigation shows markedly ↑ CK (>40x normal). Presents typically at ~4y with progressively clumsy walking. Few survive to >20y old. Refer for confirmation of diagnosis and ongoing specialist support. Genetic counselling is important. G.B.A. Duchenne (1807–75)—French neurologist.
Patient information and support
Myotonic Dystrophy Support Group 0115 987 0080
www.myotonicdystrophysupportgroup.org
Muscular Dystrophy Campaign 0800 652 6352
www.muscular-dystrophy.org
Toxic myopathies
Certain drugs can cause myopathy including:
Alcohol
Labetalol
Cholesterol-lowering drugs (including statins)
Steroids
Chloroquine
Zidovudine
Vincristine
Ciclosporin
Cocaine
Heroin
PCP
Management
Stop the implicated drug immediately. If symptoms do not resolve, refer for confirmation of diagnosis and management advice.
Acquired myopathy of late onset
Often a manifestation of systemic disease, e.g. thyroid disease (especially hyperthyroidism), carcinoma, Cushing’s disease. Investigate to find the cause. Treat the cause if found else refer for further investigation.
Polymyositis
Insidious, symmetrical, proximal muscle weakness due to muscle inflammation. Dysphagia, dysphonia, and/or respiratory muscle weakness may follow. 25% have a purple rash on cheeks, eyelids, and other sun-exposed areas (dermatomyositis) ± nail fold erythema. CK levels are ↑. Associated with malignancy in 10% of patients >40y. Refer.
PoliomyelitisND
Acute polio
Spread: droplet or faecal-oral. Incubation: 7d. Presents with 2d flu-like prodrome then fever, tachycardia, headache, vomiting, stiff neck, and unilateral tremor (‘pre-paralytic stage’). 65% who experience the pre-paralytic stage go on to develop paralysis (myalgia, LMN signs ± respiratory failure). Management: supportive—admit to hospital. <10% of those developing paralysis die. Permanent disability may result.
Prevention
1º immunization in babies and children <10y 3 doses of the 5-part vaccine (DTaP/IPV/Hib), protecting against polio, diphtheria, whooping cough, tetanus, and Haemophilus influenzae, each 1mo apart—usually at 2mo, 3mo, and 4mo. If schedule is disrupted resume where stopped
Booster doses in children 1 dose of 4-part vaccine (DTaP/IPV), protecting against polio, diphtheria, whooping cough, and tetanus >3y after the 1° course (usually pre-school), and another dose of 3-part vaccine (Td/IPV) against tetanus, diphtheria, and polio, 10y later (age 13–18y)
1º immunization in children >10y and adults Three doses of 3-part vaccine (Td/IPV), each 1mo apart. Give booster doses after 3y and 10y
Booster doses for travel Not required unless at special risk, e.g. travelling to endemic/epidemic area or healthcare workers. Boosters of Td/IPV are then given every 10y
Late effects of polio
20–30y after initial infection some patients develop new symptoms often triggered by a period of immobilization:
↑ muscle weakness and fatigue
Pain in muscles and joints
Respiratory difficulties (particularly in those who spent some time in an iron lung ventilator)—may present with symptoms relating to sleep
Once other causes are excluded, treatment is supportive.
Motor neurone disease
p. 570
Myasthenia gravis/Lambert–Eaton syndrome
p. 548
Other neurological syndromes
von Recklinghausen’s disease (type 1 neurofibromatosis; NF1)
Autosomal dominant trait. Criteria for diagnosis: ≥2 of:
≥6 café-au-lait patches (flat, coffee-coloured patches of skin seen in first year of life, increasing in number and size with age) >5mm (pre-pubertal) or >15mm (post-pubertal)
≥2 neurofibromas:
Dermal neurofibromas—small violaceous skin nodules which appear after puberty
Nodular neurofibromas—subcutaneous, firm nodules arising from nerve trunks (may cause paraesthesiae if compressed) or a plexiform neurofibroma which appears as a large subcutaneous swelling
Freckling in axilla, groin, neck base, and submammary area (women). Present by age 10y
≥2 Lisch nodules—nodules of the iris only visible with a slit lamp
Distinctive bony abnormality specific to NF1, e.g. sphenoid dysplasia
First-degree relative with NF1
Management
Ongoing specialist management is essential.
Complications
Affect 1 in 3 patients:
Mild learning disability
Short stature
Macrocephaly
Nerve root compression
GI bleeding or obstruction
Cystic bone lesion
Scoliosis
Pseudoarthrosis
↑ BP (6%)—due to renal artery stenosis or phaeochromocytoma
Malignancy (5%)—optic glioma or sarcomatous change of neurofibroma
Epilepsy (slight ↑)
F.D. von Recklinghausen (1833–1910)—German pathologist.
Type 2 neurofibromatosis (NF2)
Much rarer than type 1. Autosomal dominant inheritance.
Diagnosis
One of:
Bilateral vestibular schwannoma (acoustic neuroma—sensorineural hearing loss, vertigo ± tinnitus)
First-degree relative with NF2 and either a unilateral vestibular schwannoma or ≥1 neurofibroma, meningioma, glioma, schwannoma, or juvenile cataract
Management
Screen at-risk patients with annual hearing tests. Once diagnosis is made, specialist neurosurgical management is needed.
Complications
Schwannomas of other cranial nerves, dorsal nerve roots, or peripheral nerves; meningioma (45%); other gliomas (less common).
Ekbom’s syndrome (restless legs syndrome)
The patient (who is usually in bed) is seized by an irresistible desire to move his/her legs in a repetitive way accompanied by an unpleasant sensation deep in the legs. Sleep disturbance is common, as is +ve FH. Cause: unknown.
Management
Exclude drug causes—common culprits: β-blockers, H2 antagonists, neuroleptics, lithium, TCAs, anticonvulsants
Exclude peripheral neuropathy or ischaemic rest pain
Iron deficiency (with or without anaemia) is associated in 1 in 3 sufferers so check FBC and serum ferritin
Also check: U&E, Cr, eGFR, fasting blood glucose, and TFTs
Try non-drug measures first—reassurance, information, walking/stretching, warmth, relaxation exercises, massage
Drugs—dopamine agonists are often effective, e.g. ropinirole, pramipexole
Refer if severe symptoms or diagnosis is in doubt
K.A. Ekbom (1907–77)—Swedish neurologist
Patient support
RLS-UK 01634 260483
www.rls-uk.org
Wernicke’s encephalopathy
Thiamine deficiency causing nystagmus, ophthalmoplegia, and ataxia. Other eye signs, e.g. ptosis, abnormal pupillary reactions, and altered consciousness or confusion may also occur. Consider in any patient with symptoms and a history of alcoholism.
Management
Refer for confirmation of diagnosis. Meanwhile start thiamine 200–300mg od po to prevent irreversible Korsakoff’s syndrome. In severe cases admit as a medical emergency. K. Wernicke (1848–1904)—German psychiatrist.
Korsakoff’s syndrome
↓ ability to acquire new memories. May follow Wernicke’s encephalopathy and is due to thiamine deficiency. Confabulation to fill gaps in memory is a feature. Refer for specialist advice on management. S.S. Korsakoff (1853–1900)—Russian neuropsychiatrist.
Gilles de la Tourette syndrome
p. 911
Huntington’s disease (chorea)
Autosomal dominant trait. Testing can identify affected individuals before symptoms occur. Pre-conceptual and antenatal testing is available and should be offered to any couple with a family history on either the mother’s or the father’s side. Presents with movement abnormalities (e.g. hemichorea and rigidity) and dementia. Memory is relatively spared compared to cognition. Refer for expert advice. G. Huntington (1851–1916)—US physician.
Friedreich’s ataxia
The most common inherited ataxia (autosomal recessive). Prevalence—1:50,000. Presents in adolescence with progressive gait and limb ataxia, loss of proprioception, pyramidal weakness, and dysarthria. Extra-neurological involvement includes hypertrophic cardiomyopathy (most patients) and DM (10%). Treatment is supportive. Most patients become chairbound with in 15y and die in the 4th or 5th decade from cardiac or pulmonary complications. N. Friedreich (1825–82)—German neurologist.
Patient support
Ataxia UK 0845 644 0606
www.ataxia.org.uk
Neurological rehabilitation problems
Consider:
Is it due to an unrelated disease (e.g. change in bowel habit in someone who has had a stroke might indicate bowel cancer)?
Is it due to an incidental infection (e.g. UTI, chest infection)?
Is it due to a relapse (e.g. acute relapse in MS, TIA or further stroke in a stroke patient)?
Is it due to a side effect of treatment (e.g. acute confusion, involuntary movements or the on-off effect in a patient with PD)?
Is it part of a gradual progression (e.g. in MS, MND, brain tumour)?
Treat any cause of deterioration identified. If no cause is found, consider re-referring for specialist review and/or referring to the multidisciplinary rehabilitation team involved with the patient.
General principles of rehabilitation
p. 204
Fatigue
Consider and treat factors that might be responsible:
Depression
Chronic pain
Disturbed sleep
Poor nutrition
Action
Review support, diet, and medication; encourage graded aerobic exercise; consider a trial of amantadine 200mg/d to improve symptomsN.
Depression and anxiety
Common. Diagnosis can be difficult. Standardized questionnaires, e.g. PHQ-9 ( p. 1001), are helpful for screening.
Action
Give opportunities to talk about the impact of the illness on lifestyle. Jointly identify areas where positive changes could be made, e.g. referral to day care to widen social contact. Consider referral for counselling or to a self-help/support group. Consider antidepressant medication and/or referral to psychiatric services.
Emotionalism
If the patient cries (or laughs) with minimal provocation, consider emotionalism—impairment in the control of crying. Reassure.
Sexual and personal relationships
Problems are common. Useful information sheets are available at www.outsiders.org.uk
Communication problems
Speech therapy assessment is vital. Consider support via dysphasia groups and communication aids, e.g. simple pointing board (take advice from speech therapy and OT).
Poor vision
Refer to an optician in the first instance. If corrected vision is still poor refer for ophthalmology review.
Respiratory infections
Common. Treat with antibiotics unless in terminal stages of disease. Advise pneumococcal and influenza vaccination.
Venous thromboembolism
Common but clinically apparent in <5%. Ensure adequate hydration and encourage mobility. Consider use of aspirin 75–150mg od and compression stockings if immobile. Prophylactic anticoagulation does not improve outcome.
Motor impairment
Aim to maintain physical independence:
Involve physiotherapy—often only 2–3 visits are needed
Involve OT—a task-oriented approach is used (e.g. learning how to dress). Can also supply/advise on aids and appliances, e.g. Velcro fasteners, wheelchairs, adapted cutlery, etc
Refer for social services OT assessment if aids, equipment, or adaptations are needed for the home
Refer for home care services as necessary
Spasticity ± muscle and joint contractures
Treat with physiotherapy (usually involving exercise ± splinting) ± drugs. Anti-spasticity drugs include dantrolene (25mg od), baclofen (5mg tds or rarely through a pump), and tizanidine (2mg od). Botulinum toxin can be directed at specific muscles. Refer via the specialist rehabilitation team.
Pain
Most pain arises from ↓ mobility. Other causes include: pre-morbid disease (e.g. osteoarthritis); central pain due to neurological damage; and neuropathic pain.
Action
Chronic pain, especially central pain, may respond to TCAs. Peripheral pain may respond to simple analgesia ± physiotherapy. Other options are TENS and local joint injection. A cannabinoid is now available as an oromucosal spray (Sativex®) for relief of pain/muscle spasm in MS on specialist prescription only. Refer patients with intractable pain to specialist pain clinics.
Bladder problems
UTI If suspected, check urine dipstick ± send MSU for M,C&S and start antibiotics. If >3 proven UTIs in 1y refer to specialist incontinence service or urology for further assessment
Nocturia Desmopressin 100–400 micrograms po or 10–40 micrograms intranasally may be helpful
Urgency Modify environment, e.g. provide commode; try anticholinergic, e.g. tolterodine 2mg bd or oxybutinin 5mg tds. If not settling refer for specialist assessment
Bowel problems
Dysphagia Common. Fluids are more difficult to swallow than semisolids. Formal assessment by trained staff is essential. Feeding through NG tube or percutaneous endoscopic gastrostomy (PEG) may be needed long- or short-term—in terminal disease (e.g. MND), weigh provision of nutrition against prolongation of poor-quality life
Constipation Difficulty with defecation or BO <2x/wk—↑ fluid intake and ↑ fibre in diet. If no improvement, use po laxative ± regular suppositories/enemas
Incontinence Exclude overflow due to constipation
Skin breakdown
Prevented by: positioning; mobilization; good skin care; management of incontinence; pressure-relieving aids (e.g. special mattresses/cushions). Involve community nursing services.
Neurological assessment scales
A number of neurological assessment scales are in common use. Agreeing to use a formal, validated assessment scale enables comparison of observations between different team members, and also allows comparison of observations over time. Commonly used scales include:
Glasgow Coma Scale
Assesses level of consciousness— p. 1068
Motor scoring scale
Assesses muscle power
0—no muscle movement
1—muscle flicker but no movement
2—moves but not against gravity
3—supports limb against gravity but not resistance
4—able to overcome mild resistance (mild weakness)
5—able to overcome strong resistance (normal power)
Disability severity scales
Assess the impact of a particular condition on the individual. These scales are usually condition specific, e.g. the Migraine Disability Assessment Scale (MIDAS)—see Box 16.1, or Seizure Severity Questionnaire for patients with epilepsy. These scales are useful to gauge severity of symptoms and also monitor response to any treatments provided.
Daily living scales
A number of scales are available that measure what the individual can do in practice. These may be:
Non-disease specific e.g. Barthel Index, or
Disease specific e.g. Oxford Stroke Handicap Scale
It is not really important which scale is used as long as everyone in the team uses the same scale for any given patient. Most use a graded Likert scale (e.g. 0–5) and rate activities such as:
Mobility—walking, stairs, ability to transfer
Personal care—dressing, washing
Feeding—ability to prepare food, ability to feed self
Toileting—ability to use the toilet, continence (bowels and bladder)
Quality of life scales
Neurological conditions can have a profound impact on quality of life. Scales used to assess impact on quality of life may be completed by the patients themselves, or by the attending health professional. Examples include:
Non-disease specific scales e.g, Euroqol EQ-5D
Disease specific scales, e.g. Quality of Life in Essential Tremor (QUEST); Quality of Life in Epilepsy (QUOLIE)
Cognitive function tests
e.g. The General Practitioner Assessment of Cognition (GPCOG), or 6 Cognitive Impairment Test (6CIT— p. 1011).
Mental health scales,
e.g.
Month: | Total Views: |
---|---|
October 2022 | 2 |
February 2023 | 3 |
June 2023 | 1 |
July 2023 | 1 |
September 2023 | 2 |
October 2023 | 3 |
November 2023 | 2 |
January 2024 | 2 |
February 2024 | 2 |
March 2024 | 1 |
May 2024 | 1 |
June 2024 | 2 |
August 2024 | 11 |
September 2024 | 2 |
December 2024 | 1 |
February 2025 | 4 |
April 2025 | 1 |